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INVESTIGATIONS  OF  INTERLEUKIN-­1  ALPHA  AS  A  NOVEL  STROKE  
THERAPY  IN  EXPERIMENTAL  ISCHEMIC  STROKE  
  
Stroke  is  a  leading  cause  of  death  and  disability  worldwide.  Although  rapid  
recognition   and   prompt   treatment   have   dropped   mortality   rates,   most   stroke  
survivors  are  left  with  permanent  disability.  Approximately  87%  of  all  strokes  result  
from  the  thromboembolic  occlusion  of  the  cerebrovasculature  (ischemic  strokes).  
Potential   stroke   therapeutics   have   included  anti-­inflammatory   drugs,   as  well   as  
many  other  targets  with  the  goal  of  mitigating  the  acute  and  chronic  inflammatory  
responses  typically  seen  in  an  ischemic  stroke.  While  these  approaches  have  had  
great   success   in   preclinical   studies,   their   clinical   translation   has   been   less  
successful.  Master  inflammatory  cytokines,  such  as  IL-­1,  are  of  particular  interest.  
IL-­1’s  isoforms,  IL-­1a    and  IL-­1b,  were  long  thought  to  have  similar  function.  While  
IL-­1b  has  been  extensively  studied  in  stroke,  the  role  of  IL-­1a  during  post  stroke  
inflammation   has   been   overlooked.   Because   IL-­1   inhibitors   have   been  
unsuccessful  in  clinical  application,  we  reasoned  that  IL-­1a  may  provide  previously  
unknown  benefits  to  the  brain  after  injury.    We  hypothesized  that  IL-­1a  could  be  
protective  or  even  accelerate  reparative  processes  in  the  brain  such  as  producing  
new  blood  vessels  (angiogenesis)  or  neurons  (neurogenesis).    
  
To   test   that   IL-­1a   is   protective   after   stroke,  we   tested   IL-­1a’s   protective  
effects  on  primary  cortical  neurons  in  in  vitro  models  of  stroke.  We  showed  that  IL-­
1a   was   directly   protective   on   primary   cortical   neurons   in   a   dose-­dependent  
fashion.  We  then  performed  mouse  middle  cerebral  artery  occlusion  stroke  studies  
to   determine   the   safety   of   giving   IL-­1a   in   vivo.   These   studies   showed   that  
administering   IL-­1a   acutely   was   neuroprotective.   However,   intravenous   (IV)  
administration  of  IL-­1a  resulted  in  transient,  hemodynamic  changes  following  drug  
delivery.  To  minimize  these  systemic  effects,  we  administered  IL-­1a  intra-­arterially  
(IA)  directly  into  the  stroke  affected  brain  tissue,  allowing  us  to  significantly  lower  
the  concentration  of  administered   IL-­1a.      In  comparison   to   IV,   IA   IL-­1a  showed  
greater  histological  protection  from  ischemic  injury  as  well  as  improved  functional  
recovery  following  stroke,  all  without  systemic  side  effects.  
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To  test   that   IL-­1a  could  aid   in  neurorepair   following  stroke,  we  tested  IL-­
1a’s   ability   to  help  damaged  blood  vessels   repair   in   vitro.  We   found   that   IL-­1a  
significantly  increased  brain  endothelial  cell  activation,  proliferation,  migration,  and  
capillary   formation.   We   tested   IL-­1a’s   proangiogenic   properties   in   vivo   by  
administering  IL-­1a  three  days  following  stroke.  Delayed  administration  allowed  us  
to   separate   IL-­1a’s   acute   neuroprotective   effects   from   potential   subacute  
angiogenic   effects.  We   found   that  mice   receiving   IL-­1a   performed   significantly  
better   on   behavioral   tests   and   also   showed   greater   vascularization   within   the  
penumbra  two  weeks  following  stroke.  We  also  found  that  IL-­1a  treated  animals  
showed   more   endothelial   activation   than   vehicle   treated   animals.   Finally,   our  
studies   showed   that   IL-­1a   treated   animals   showed   increased   early-­phase  
neurogenesis  with  evidence  of  increased  proliferation  at  the  subventricular  zone  
suggesting   that   IL-­1a’s   beneficial   effects   are   even   more   far-­reaching   than  
previously  thought.  In  conclusion,  our  experiments  suggest  that  the  inflammatory  
cytokine   IL-­1a   is   neuroprotective  and  neuroreparative   in  experimental   ischemic  
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Chapter  1:  Introduction  
Edema  and  BBB  Breakdown  in  Stroke  
Kathleen  E  Salmeron,  Danielle  N.  Edwards.  Justin  F.  Fraser,  and  Gregory  J.  Bix  
University  of  Kentucky,  Lexington,  KY,  United  States  
  
Introduction:  
Stroke  is  a  leading  cause  of  death  and  disability  affecting  15  million  people  
worldwide.  Although  rapid  recognition  and  treatment  have  dropped  mortality  rates,  
many  are   left  with  permanent  disability.  Approximately  87%  of  all  strokes   result  
from  the  thromboembolic  occlusion  of  the  cerebrovasculature  (ischemic  strokes)  
(1).  Current   research  distinguishes  between  zones  of   core   infarct   and  areas  of  
metabolically   compromised   but   potentially   viable   tissue   receiving   collateral  
circulation   known   as   penumbra   (2).   Research   has   long   focused   on   how  
endogenous  mechanisms   of   neuroprotection   and   neurorepair   affect   penumbral  
expansion.   Such   therapeutic   approaches   have   included   antiinflammatory  
interventions,  reactive  oxygen  species  (ROS)  scavengers,  and  many  other  targets  
with  the  common  goal  of  mitigating  the  acute  and  chronic  inflammatory  responses  
typically  seen  in  an  ischemic  stroke.  This  chapter  will  discuss  acute  and  chronic  
molecular  mechanisms  underlying  edema  following  ischemic  stroke.    
Despite   advancements   in   reperfusion   and   recanalization   through  
intravenous   tPA   and   mechanical   thrombectomy,   stroke   still   often   results   in  
significant  disability   (3).  Edema  and   inflammation  compound   the   injury  and  can  
turn   a   disabling   infarct   into   a   deadly   lesion   causing   mass   effect   (4).   Despite  
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advancements   in   recanalization,   the   expansion   of   ischemic   injury   occurs  
regardless  of  the  restoration  of  blood  flow  (5,6,7,8).  A  key  component  of  such  injury  
expansion  is  the  breakdown  of  the  blood–brain  barrier  (BBB)  (5,9).  Here,  we  will  
examine  how  this  breakdown  leads  to  brain  swelling  (edema).  To  do  this,  we  the  
first  need  to  understand  the  composition  and  physiologic  function  of  the  BBB.    
Physiologic  Structure  and  Function  of  the  Blood-­Brain  Barrier  
Under  physiologic  conditions,  the  BBB  separates  the  healthy  brain  from  the  
systemic   blood   supply.   It   is   a  multilayered   unit  made   up   of   astrocytic   endfeet,  
extracellular  matrix   (ECM),  microglia,   pericytes,   and   nonfenestrated   capillaries,  
which   are   tightly   interconnected   in   order   to   protect   the   brain   parenchyma   from  
noxious  substances  in  blood  such  as  immune  cells  and  cytokines.  Moreover,  the  
BBB   is   also   responsible   for   regulating   the   flow   of   nutrients   into   the   brain   and  
metabolic  by-­products  out  of  the  brain,  thereby  helping  to  maintain  a  healthy  brain  
environment  (10,  11).  Specifically,  although  the  vasculature  in  the  majority  of  the  
brain   is   tightly   contained,   astrocytes   with   endfeet   in   close   proximity   to   the  
vasculature  are  tasked  with  filtering  nutrients  and  water  into  the  brain  parenchyma  
and  delivering  them  to  neurons  (11,  12).  Importantly,  astrocytes  remain  unreactive  
under  normal  conditions  (13).  Astrocytic  endfeet  are  anchored  to,  and  separated  
from   the   endothelium   by,   the   ECM   (10,   11).The   same   is   true   with   vascular  
endothelial   cells,   which   are   anchored   to   the   matrix.   Previously,   biochemists  
believed   that   the   ECM  was   just   a  water-­based   substance   that   filled   the   space  
between   cells   throughout   the   body.   Today,   we   know   that   the   matrix   provides  
crucial  signal   transduction  proteins,  scaffolding  for  cell  stability  and  motility,  and  
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facilitates  homeostasis  (14).    
Among  the  most  important  cellular  signaling  receptors  that  interact  with  the  
ECM  are   integrins.  These   interactions  with  ECM  components  such  as  collagen,  
laminin,  and  fibronectin,  aid  in  cell  signaling,  activation,  and  migration  (11,  15-­19).  
In  addition,  brain  endothelial  cells  form  intercellular  barriers  called  tight  junctions  
(TJs),  made  up  of  TJ  proteins  including  claudin,  occludin,  and  junction  adhesion  
molecules   (11).   TJs   are   responsible   for   regulating   and  maintaining   the   relative  
impermeability  of  the  brain  parenchyma  to  cells  as  well  as  to  large  molecules  (10,  
11).  Pericytes,  while  not  as  well  understood,  are  thought  to  aid  in  this  regulation  of  
BBB  permeability  under  normal  conditions  (20,  21).  Taken  together,  the  barrier  is  
essential   for  protecting   the  brain  parenchyma  and,   if  disturbed,  can   result   in  or  
exacerbate  brain  injury.    
The  Phases  of  Edema  in  Stroke  
Stroke   occurs   in   three   main   phases:   acute   (can   be   further   split   into  
hyperacute   and   acute   phases),   subacute,   and   chronic.   The   hyperacute   phase,  
occurring  within   the   first  several  minutes  of  stroke  onset,   is   the  phase   in  which  
clinical  symptoms  appear  but  is  not  the  phase  in  which  most  damage  occurs.  The  
second  phase,  the  acute  phase,  occurs  within  the  first  few  hours  of  a  stroke  and  is  
the  phase  in  which  most,  if  not  all,  clinical  intervention  must  occur  for  there  to  be  
any  positive  change   in  patient  outcome   (2).  The  subacute  phase  occurs  24–48  
hours  after  onset.  This  phase  is  difficult  to  define  because  the  infarct  has  not  yet  
reached  its  maximum  volume.  It  is,  however,  past  the  therapeutic  window  for  either  
IV   t-­PA  or   for   endovascular   thrombectomy   (2,   12,   22,   23).   The   final   or   chronic  
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phase  can  last  for  1–2  weeks.  This  is  the  phase  wherein  the  brain  pathophysiology  
transitions  from  neuroprotective  to  neuroreparative  mechanisms  (11,  12,  22).    
The  Hyperacute  Phase:  The  First  Few  Minutes  
The  brain’s  response  to  an  ischemic  event  is  swift.  Because  the  cells  are  
not   receiving   the  oxygen  and  energy   that   they  need,   ion  pumps   fail   to  maintain  
homeostatic  sodium  and  potassium  concentrations,  resulting  in  calcium  influx  into  
the   cytoplasm.   This   rapid   ion   exchange   causes   excitatory   cells   (neurons)   to  
depolarize   in   a   process   called   anoxic   depolarization   (24),   which   releases  
glutamate   into   the   extracellular   space.   Astrocytes,   in   carrying   out   their  
physiological  function,  take  up  the  released  glutamate  using  the  glutamate–sodium  
cotransporter.  In  addition,  the  further  influx  of  water  through  channels,  known  as  
aquaporins,   causes   osmotic   swelling   of   the   cell   (2,   25).   The   end   result   is   that  
neurons   and   astrocytes  within   the   ischemic   core   terminally   depolarize   and  will  
eventually   undergo   apoptosis.   Some   studies   have   shown   that   blockade   or  
selective   knock-­down   of   these   aquaporins,   particularly   aquaporin-­4,   helps   to  
prevent   the   formation   of   metabolic   edema   after   events   such   as   stroke   and  
traumatic  brain  injury  (12,  25).    
Meanwhile,   the  cells  of   the  neurovascular  unit   release  Hypoxia   Inducible  
Factors   (HIFs)  as  well  as  other  signaling  molecules,  which   rapidly  activate  glial  
cells.  HIFs  are  typically  not  released  in  sufficient  quantities  to  initiate  widespread  
effects.   Local   astrocytes   and   microglia;;   however,   will   release   pro   and  
antiinflammatory  cytokines  and  other   inflammatory  markers   into   the  core  of   the  
infarcted  area  (23).  This  release  of  inflammatory  mediators  results  in  acute,  local  
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swelling,   which   triggers   a   decrease   in   diameter   of   the   vasculature   (11,   12).   In  
addition,   many   of   the   cytokines   released   by   glial   cells   cause   a   breech   in   the  
integrity  of  the  BBB  (23).  Although  this  process  is  just  beginning  within  the  first  few  
minutes  of  ischemia,  these  early  initial  events  set  up  a  cascade  of  longer  lasting  
(up  to  2  weeks)  consequences.    
The  Acute  Phase:  The  First  Hours  
At   the  onset  of  an   ischemic  stroke,  a  patient  has  very   limited   time  to  get  
treatment   to   reperfuse   brain   tissue.   On   the   contrary,   reperfusion,   whereas  
necessary,   can   introduce   new   cascades   that   do   compound   damage.   In   the  
hyperacute  phase,  endothelial  cells   release  pro  and  antiinflammatory  cytokines,  
which  begin  to  cause  the  opening  and  closing  of  the  BBB  (11).  The  mechanism  by  
which  this  opening  occurs  is  relatively  unknown.  However,  the  open  barrier  allows  
the   infiltration   of   potentially   harmful   leukocytes   and   neutrophils   (26).   These  
immune  cells  attach  to  the  vascular  endothelial  cell  barrier  due  to  an  increase  in  
the   interaction  between  selectins,   the   immunoglobulin   (IG)  superfamily   such  as  
ICAM  1  and  2  and  VCAM-­1,  and  integrins  (19,  27).  This  attachment  triggers  the  
leukocytes  to  release  many  proinflammatory  mediators  into  the  brain  parenchyma  
(23).  The  members  of  the  IG  superfamily  are  indirectly  activated  by  ischemic  injury  
but  are  directly  activated  by  the  release  of  cytokines  in  a  biphasic  response  (11,  
28),  with  the  degree  of  ischemia  dictating  the  amount  of  cytokine  that  is  released  
(28).    
If  the  amount  of  cytokine  reaches  a  certain  threshold,  the  BBB  opens  wide  
enough   to   allow   the   attached   leukocytes   and   neutrophils   to   properly   infiltrate  
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through  new  gaps   in   the  endothelial   cell   layer  and  pass   through  gaps  between  
astrocytic  endfeet  and  endothelial  cell  adhesions  into  the  brain  parenchyma  (19).  
These   inflammatory   cells   release   cytokines   into   the   injured   area   in   excess  
concentrations   than   are   common   in   the   brain,   thus   exacerbating   astrocyte   and  
microglia  activation  (13).  Elevated  brain  cytokine  levels  also  contribute  to  neuronal  
apoptosis,  thereby  expanding  the  area  of  permanent  ischemic  damage  (2).  Cellular  
milieu   released   during   apoptosis   causes   further   activation   of   astrocytes   and  
microglia  in  the  penumbral  tissue  (29,  30).  Astrocytes  and  microglia,  in  turn,  also  
release   reactive   chemicals   as   part   of   their   scavenging   and   damage   control  
mechanisms  (13).  Activated  astrocytes   release   inflammatory  mediators  such  as  
cytokines,  chemokines,  and  inducible  nitric  oxide  synthase  (iNOS)  (31);;  the  latter  
is  particularly  problematic  because   it   is  a  mediator  of  DNA  damage   through   its  
synthesis  of  ROS  (discussed  later  in  this  chapter)  (32,  33).    
Microglia,  acting  originally  as  the  brain’s  macrophages,  become  much  more  
like  phagocytes,   releasing  cytotoxic   factors   into   the  surrounding   tissue  (23,  34).  
This  process  persists  throughout  the  subsequent  phases  of  ischemia  and  induces  
secondary   mechanisms   of   injury.   On   the   contrary,   these   mechanisms   are   not  
halted  once  a  patient  is  recanalized  (Figures  1  and  2).    
Electrically,  the  spread  of  the  ischemic  penumbra  can  be  partially  explained  
by   phenomena   known   as   periinfarct   spreading   depression-­like   depolarizations  
(PIDs)   (2).   This   largely   accepted  and  widely   studied  hypothesis   states   that   the  
expansion  of  the  penumbra  is  due  in  part  to  bioelectrical  disturbances  caused  by  
the   combination   of   an   increased   energy   demand   of   penumbral   cells   and   the  
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decreased  energy  supply  due  to   ischemia.  These   intermittent  depolarizations  of  
neurons  proximal  to  the  core  cause  widespread  energy  demand  by  surrounding  
neurons.  An  increase  in  energy  demand  without  adequate  energy  supply  causes  
further   terminal  depolarization.  Each  one  of   these  PIDs  may  even   increase   the  
infarct  volume  by  more  than  20%  (34,  35).  Moreover,  PIDs  are  implicated  in  many  
more  downstream  mechanisms  of  secondary  injury  (discussed  below)  such  as  the  
formation  of  ROS,  DNA  damage,  and  mitochondrial  dysfunction   (2,  34).   In   fact,  
many  researchers  believe  that  this  mechanism  holds  the  key  to  pharmacological  
interventions   for   stroke   patients.   The   PID   phenomena   is   just   one   of   the  many  
excitotoxic  pathways  by  which  infarcts  develop,  and  it  is  by  this  mechanism  that  
receptor  blockers  and  antagonists  (glutamate,  NMDA,  etc.)  act  (36).    
The  Patient  in  the  Clinic:  Reperfusion  and  Edema  
Most  brain  injury  that  has  thus  far  occurred  is  from  ischemia  brought  on  by  
the   clot,   but   by   removing   the   thromboembolic   blood   clot   (recanalization)   and  
allowing   normal   blood   flow   (reperfusion)   the   brain   is   exposed   to   not   only   the  
oxygen  and  nutrients  that  it  needs  but  also  to  deleterious  components  of  the  blood  
due  to  the  pathologic  opening  of  the  BBB  (11).  Edema  caused  by  recanalization  
can  be  fatal  (37,  38).  The  mechanisms  of  this  deterioration  have  until  recently  been  
poorly  understood   (4).  This  acute  worsening  condition   in  some  patients  can  be  
partially   explained   by   the   observation   that   many   of   them   did   not   achieve  
recanalization.   Another   well-­studied   hypothesis   is   that   it   is   due   in   part   to   the  
aforementioned  biphasic  opening  of  the  BBB  (4).  This  opening  allows  the  influx  of  
materials  from  the  blood,  mainly  fibrin  and  fibrinogen  from  the  blood  clot,  to  enter  
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the  infarct  (10,  39-­43).  Once  the  fibrin  and  fibrinogen  exit  the  lumen,  the  rate  of  
translocation   of   leukocytes   increases   (44   -­   46),   activating   microglia,   and   thus  
phagocytosis   (47)   and   binding   receptor   ICAM-­1   (10),   the   same   as   described  
above.  In  addition,  fibrinogen  is  able  to  inhibit  the  growth  of  new  neurites  (10,  48)  
as  well  as   inhibit  axon   regenerations,  preventing   rejuvenation  of   the   tissue  and  
allowing   symptoms   to   remain   and   progress   (10).   As   such,   current   trends   in  
recanalization   therapy,   specifically   selection   of   patients   for   mechanical  
thrombectomy,  seek  to  use  imaging  modalities  to  select  patients  for  recanalization  
who  are  most  likely  to  benefit.  This  continues  to  lead  to  avenues  in  research,  as  
imaging  modalities  and  rapid  systems  of  stroke  care  seek   to  avoid   recanalizing  
tissue  in  which  the  balance  of  risk/benefit  tilts  toward  induction  of  further  harm.    
Edema  
All   of   the   above   circumstances   can   lead   to   edema.   Although   edema   is  
considered  a  poor  outcome  in  peripheral  tissues,  it  is  potentially  deadly  in  the  brain  
(49).  Of  the  four  specific  kinds  of  edema  (intravascular,  extracellular,  intracellular,  
and  hydrocephalic  or  CSF  edema)  (50),  clinicians  can  see  all  of   them   in  stroke  
patients.   Although   edema   is   typically   thought   of   in   the   circumstances   of   wet  
edema,   nearly   all   of   the   damage   seen   in   stroke   is   caused   by   cytotoxic,   or  
metabolic,   edema   (50).   Metabolic   edema   is   so   named   for   its   characteristic  
disruption   of   metabolic   homeostatic   processes,   in   particular   the   sodium   pump  
discussed   earlier.   This   cytotoxic   edema   causes   upregulation   of   matrix  
metalloproteases  that  disrupt  TJs  and  other  components  of  the  BBB  resulting  in  
further   swelling   (51,   52).   As   the   barrier   continues   to   open,   the   influx   of  
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proinflammatory   proteins   and   cells   lead   to   a   state   of   secondary   inflammation,  
which  will  be  discussed  later.  It  is  important  to  note,  however,  that  this  secondary  
inflammation  pathway  forms  in  the  periphery  of  the  ischemic  tissue  presumably  to  
aid  in  the  protection  of  healthier  tissue.    
In   addition,   edema   is   nearly   impossible   to   effectively   mitigate.   The  
immediate   process   of   ischemic   stroke   causes   primarily   cytotoxic   edema   in   the  
injured  tissue  (50).  Although  this  is  typically  well-­tolerated  in  cases  of  small  strokes,  
it   can   compound   brain   injury   and   even   cause   death   in   two   particular   types   of  
ischemic  strokes.  Large  anterior  circulation  strokes  involving  the  middle  cerebral  
artery  territory  can  cause  significant  compression  of  the  brain  and  uncal  herniation  
due  to  edema  (53).  In  the  posterior  fossa  in  which  the  potential  space  is  smaller,  
strokes  of  the  cerebellum  (Figure  1.1)  and  brainstem  (even  relatively  small  in  size)  
can   result   in   significant   edema,   which   then   further   compresses   the   brainstem,  
resulting   in   obstruction   of   outflow   of   cerebrospinal   fluid.   Obstruction   of   the   4th  
ventricle  and   its  outflow   results   in  hydrocephalus,  which   further  compounds   the  
compressive   damage   to   the   brain.   Either   of   these   cases   can   quickly   result   in  
neurological   injury  and  death.  As  such,  multiple   studies  and  guidelines  support  
decompression  of  ischemic  strokes  in  the  posterior  fossa  and  in  selected  patients  
with   MCA   strokes.   Surgical   decompression   (Decompressive   Craniectomy)  
involves   the   removal   of   the   overlying   skull,   opening   of   the   dura,   and,   in   some  
cases,  resection  of  the  ischemic  tissue  (54-­56).  This  provides  a  space  into  which  
the   edematous   tissue   can   swell,   reducing,   and,   in  most   cases,   eliminating   the  
compressive  forces  on  the  brain  and  brainstem  (51).  It  can  also  improve  perfusion  
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to   ischemic   tissue,   most   notably   to   the   penumbral   areas   (57).   Besides  
decompression,   there   are   tenets   of   medical   therapy   designed   to   minimize   the  
edema,   though   they   are   not   as   effective   for   the   cytotoxic   edema   present   in  
ischemic  stroke  (51,  58).    
The  Subacute  Phase:  24-­48  Hours  
On   the   contrary,   the   patient’s   struggle   with   edema   does   not   end   upon  
recanalization.   In   fact,   some   patients   worsen   during   the   subacute   phase   of   a  
stroke.  Inflammatory  cytokines  and  ROS  continue  to  cause  devastating  damage  
until  the  infarct  achieves  maturity.  The  massive  increase  in  cytokine  release  occurs  
cyclically;;  injury  mediates  cytokine  release,  causing  further  injury,  which  mediates  
more   cytokine   release.   In   particular,   cytokines  MCP-­1,   interleukin-­1   (IL-­1),   and  
TNF-­α  are  upregulated  (18,  59).  There  is  a  biphasic  upregulation  in  the  brain  after  
ischemia  of  IL-­1β  within  minutes  and  of  TNF-­α  within  hours  of  injury  (60-­63).  MCP-­
1  is  upregulated  in  astrocytes  and  brain  endothelial  cells,  allowing  for  an  increase  
in  leukocyte  infiltration  (16,  18).  Chemokines  are  also  released  after  ischemia  to  
recruit   inflammatory   and   immune   responses   such   as   increasing   leukocyte  
infiltration   to   the   vascular   wall   (64).   There   are   four   groups   associated   with  
chemokines,  C,  CC,  CXC,  and  CX3C  (65).  Their  increase  has  been  shown  to  occur  
and  localize  to  neurons  in  the  brain  (65,  66).  The  stimulated  immune  response  by  
all  the  above  factors  also  activates  the  arachidonic  acid  cascade  (67)  causing  an  
influx  of   calcium   (2)   due   to   the  disruption  of   the  ATP-­dependent   calcium  efflux  
mechanisms   and   SERCA   on   endothelial   cells   (17,   68),   and   a   conversion   of  
arachidonic   acid   to   prostaglandins   (19).   These   processes   occur   over   a  
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spatiotemporal  gradient  meaning   that   it  occurs  over  an  extended  period  of   time  
and  contributes  to  penumbral  expansion  (13).    
Inflammatory   mediators   such   as   cytokines   and   chemokines   are   not   the   only  
deleterious  molecules   to   be   released   in   the   brain   during   injury.   ROS,   such   as  
superoxide,  peroxide,  and  hydroxyl  anion  (11),  which  are  the  most  damaging,  are  
produced  as  normal  by-­products  of  energy  producing  mechanisms,  particularly  the  
electron  transport  chain  occurring  in  the  mitochondria,  and  are  necessary  for  some  
normal   cell   signaling   (69).   During   injury,   these   ROS   are   able   to   build   up   in  
damaging   amounts   by   overcoming   the   scavenging   mechanisms   and   by  
intracellular  increases  in  calcium,  sodium  and  adenosine  as  a  direct  result  from  the  
ischemic   injury.  This   results   in  damage   to  signaling  pathways,  TJ  proteins,  and  
enzyme  activation  (11,  70).    
Isoforms   of   nitric   oxide   (NO),   enodothelial-­NOS   (eNOS),   neuronal-­NOS  
(nNOS),  and  iNOS,  indirectly  produce  ROS  through  signaling  pathways  (11,  71).  
An  increase  in  both  the  calcium-­independent  iNOS  and  calcium-­dependent  nNOS  
in  both  the  core  and  penumbra  after  24–48hours  corresponds  with  the  increase  in  
symptoms  and  the  size  of  the  infarct  volume  (11,  32,  33).    
The  Chronic  Phase:  3  Days-­2  Weeks  
During  the  first  week  after  a  patient  suffers  a  stroke,  there  are  a  multitude  
of  changes  that  go  on  in  the  brain.  The  lesion  volume  continues  to  increase  until  
days  3–8  post-­stroke  and  subsequently  decreases  in  size  (72).  In  fact,  the  lesion  
continues  to  change  up  to  30  days  after  stroke  onset  (73).  Edema  may  persist,  and  
the   patient   may   remain   hospitalized.   Despite   all   of   this,   the   brain   is   doing  
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remarkable  things  to  repair  itself.  The  vasculature  is  rebuilding  itself  by  means  of  
angiogenesis,   which   inadvertently   results   in   a   more   open   BBB   due   to   the  
generation  of  leaky  neovasculature  (11,  40,  74).  This  process  serves  not  only  to  
rebuild  and  revascularize  dead  brain  but  also  to  serve  as  a  scaffold  network  for  
neuronal  progenitor  cells  (NPCs)  to  migrate  along  in  their  efforts  to  repopulate  and  
regenerate  the  infarcted  area  (74).  Indeed,  the  newly  generated  periinfarct  blood  
vessels,   driven   by   post   stroke   increases   in   angiogenic   growth   factors   such   as  
VEGF  and  angiopoietin-­2,  appear   to  be  overall   less  effective  at   restoring  blood  
flow  to  ischemic  brain  and  more  linked  to  forming  a  protective  neurovascular  niche  
for  guiding  NPCs  toward  the  site  of  injury.  As  such,  these  nascent  blood  vessels  
are  tortuous  and  leaky  and  often  support  little  to  no  active  blood  flow  as  this  would  
only  further  worsen  potential  hemorrhage  and  edema  into  periinfarct  brain  (75).    
The   brain’s   repair   pathways   appear   to   be   largely   inadequate   and   may  
represent  a  simple   reactivation  of  dormant  developmental  pathways.  Significant  
research  effort  has  focused  on  improving  neurorepair  pathways  (74,  76).  For  one  
example,   the  activated  and  migrated  astrocytes   in   the   infarcted   region  undergo  
astrogliosis  forming  an  area  of  scarring  that  forms  a  physical  barrier  that  prevents  
new  neurons  from  repopulating   the  dead  region.  This  results   in  very   few  neural  
progenitor  cells  reaching  the  infarcted  brain  region  (77).    
Another   problem   that   NPCs   face   is   that   even   those   that   reach   their  
termination  site  often  do  not  differentiate  into  a  neuronal  line.  In  fact,  only  about  
1%  of  the  NPCs  born  at  the  subventricular  zone  mature  into  neurons  (77).  Current  
research   has   aimed   to   encourage   the   repopulation   of   the   region   with   mature  
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neurons  by  administering  trophic  factors  to  the  site  of  injury.  Thus  far,  these  trials  
have   met   little   success.   Other   labs   have   administered   NPCs   directly   into   the  
infarct.   These   experiments   have   met   marginally   greater   success   but   still   not  
enough  to  make  a  clinical  impact  (74)  as  the  NPCs  tend  to  exacerbate  scarring  by  
differentiating  in  a  non-­neuronal  pathway.  Still  other  labs  have  worked  to  reduce  
astrogliosis,  which  would,  in  theory,  revitalize  repopulation  efforts  (13).  
Summary  
Stroke   is   a   devastating   event   that   affects  millions   of   people   every   year.  
Although   much   research   is   conducted   to   improve   stroke   therapy,   more   work  
remains  to  improve  patient  outcomes.  Although  most  research  to  date  has  focused  
on  mitigating  events  happening  in  the  hyperacute  and  acute  phases  after  stroke  
(Figure  1.2),  a  tremendous  need  persists  to  prevent  or  mitigate  later  events  such  
as   edema.   Edema,   secondary   to   disruption   of   the   BBB,   significantly   worsens  
ischemic  stroke  brain   injury   in  part  via  mass  effect  expansion  of   the  brain   in   its  
finite  cranial  vault,  a  process  that  can  lead  to  fatal  brain  herniation  if  left  unchecked.  
Indeed,   our   few   current   therapeutic   options   for   ischemic   stroke   that   target  
dislodging   or   dissolving   the   at   fault   blood   clot,   actually   further   exacerbate   the  
potential  of  BBB  breakdown  and  edema  via  resultant  hyperemia.  Therefore,  our  
success   at   targeting   the   offending   blood   clot   must   be   paired   with   additional  
therapeutic  approaches  designed  to  limit  or  eliminate  subsequent  edema  if  we  are  
to  make  significant  gains  in  ischemic  stroke  treatment.  In  addition,  a  renewed  focus  
on  neurorepair  strategies  may  also  yield  better   therapies   to  minimize   long-­term  
disability  that  is  common  even  with  the  current  standard  of  care  therapy.    
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Figure  1.1:  39-­year-­old  female  with  underlying  coagulopathy  presented  with  a    
cerebellar   stroke   with   significant   edema   and   underwent   decompression.   MRI  
FLAIR  sequence  showing  large  left  cerebellar  stroke,  compression  of  brainstem  
and  4th  ventricle  (A).  Postoperative  CT  shows  craniectomy  and  partial  lobectomy  





occlusion   of   internal   carotid   and   anterior/middle   cerebral   arteries   underwent  
successful   intravenous   tPA   and   mechanical   thrombectomy   but   developed  
significant  edema  requiring  decompression.  MRI  FLAIR  sequence  showing  large  
left   MCA   territory   edema   from   some   infarction   (C).   Postoperative   CT   shows  





















Figure  1.2:  Overview  of  the  cyclical  and  compounding  nature  of  edema  and  stroke.  
Stroke   causes  apoptosis   due   to   lack  of   oxygen  and  nutrients   in   the  brain.  The  
introduction   of   inflammation   contributes   to   edema   through   the   release   of  
inflammatory   cytokines,   water,   and   the   infiltration   of   leukocytes   into   the   brain  
parenchyma.   Reactive   oxygen   species   contribute   to   glutamate-­mediated  
excitotoxicity,  which   results   in   further   apoptosis   thereby  expanding   the  dead  or  






The  IL-­1  Family  of  Cytokines  
Introduction  
   The  section  above  focused  on  how  the  blood  brain  barrier’s  breakdown  and  
how  the  dysregulation  of   inflammatory  mediators   influence  post   ischemic   injury.  
This   clearly   outlines   the   need   for   future   efforts   in   identifying   better   therapeutic  
strategies   for   post   stroke   intervention.   As   previously   stated,   pro   and   anti-­
inflammatory  cytokines  are  among  the  most  prominent  inflammatory  players  in  the  
process  of  injury  evolution  after  stroke  (18).  The  cytokines  of  most  interest  to  our  
lab  are  the  interleukin  cytokines.    
Coined  in  1979,  the  interleukin  cytokines  are  so  named  because  they  were  
discovered  as  factors  that  were  secreted  from  leukocytes  (78,  79).  There  are  many  
interleukins  which  are  differentiated  from  each  other  based  on  their  assignment  to  
families;;  however,   this  categorization  has  undergone  several   rounds  of   revision  
since   the  discovery  of   interleukins   (79).  Families  are  so  differentiated  based  on  
primary  and  secondary  protein  structure  as  well  as  by  publication  date  (80)  and  
are  noted  by  a  dash  followed  by  a  number  such  as  (IL-­1,  IL-­4,  and  IL-­6).  Many  of  
these  families  can,  within  them,  encompass  one  or  more  isoforms.  The  different  
isoforms   are,   in   many   cases,   then   noted   by   additional   identifiers   (many   times  
Greek  letters)  following  the  familial  number.  The  cytokine  family  of  interest  for  our  
lab  is  the  IL-­1  family  of  cytokines.  The  IL-­1  family  contains  three  “classic”  isoforms:  
IL-­1a,   IL-­1b,   and   the   endogenous   IL-­1   receptor   antagonist   (RA)   (81).      While  
isoforms  from  the  same  cytokine  family  are  classified  for  different  reasons,  the  IL-­
1a  and  IL-­1b  isoforms  in  the  IL-­1  family  were  once  a  single  gene  which  underwent  
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evolutionary  divergence  (79).  Evidence  also  exists   that,  despite   IL-­1b  being   the  
more  thoroughly  studied  of  the  IL-­1  isoforms,  IL-­1b  diverged  from  IL-­1a.  In  1986,  
a  study  was  done  that  showed  that  the  pro  form  of  IL-­1b  derives  from  a  reverse  
transcribed  pro-­IL-­1a  (82).  Since  then,  IL-­1a  and  IL-­1b  have  been  shown  to  have  
key  differences  in  their  production  and  in  their  physiologic  function  (83).  Despite  
this,  many  researchers  in  the  field  of  neuroinflammation  still  take  for  granted  that  
IL-­1a  and  IL-­1b  hold  similar  function  (84).  In  the  following  sections,  we  will  discuss  
the  principle  isoforms  of  IL-­1  (IL-­1a,  IL-­1b),  the  IL-­1  receptors  (IL-­1R1,  2,  and  3),  
and  IL-­1RA  in  terms  of  their  regulation,  cellular  role  under  normal  conditions,  and  
role  in  pathogenesis.  
  
Key  Differences  Within  the  IL-­1  Family  
IL-­1b  is,  perhaps,  the  most  well  studied  of  the  IL-­1  family  of  cytokines  and  
is  also  believed  to  be  the  most  relevant  to  human  health  and  disease.  In  contrast  
to  IL-­1b,  IL-­1a  is  the  least  studied  IL-­1  family  both  in  the  context  of  stroke  and  in  
other   human   diseases   (84).      As   mentioned   previously,   the   two   IL-­1   isoforms  
evolutionary  diverged  to  form  two  distinct  proteins  (79).  This  divergence  is  reflected  
in  the  primary  structures  of  IL-­1a  and  IL-­1b.  The  two  isoforms  only  carry  around  
23%  identity  and  40%  similarity  in  their  primary  amino  acid  sequence  (79).  Despite  
the   significant   difference   in   primary   structure,   both   isoforms   carry   a   similar  
secondary  and  tertiary  protein  structure.  In  fact,  all  of  the  classical  IL-­1  cytokines  
carry  a  very  similar  folding  structure  (79).  IL-­1a,  IL-­1b  and  IL-­1RA  all  hold  a  central  
structure  containing  12  stacked  b-­sheets  known  as  a  b-­trefoil  (79,  85,  86,  87).  Both  
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IL-­1a  and   IL-­1b  are  both   transcribed  as  pro-­cytokine  proteins.  A  key  difference  
between  these  two  pro-­cytokines  is  that,  while  pro-­IL-­1b  must  be  processed  to  its  
mature  form  to  achieve  biological  activity,  pro-­IL-­1a  carries  nearly  equal  bioactivity  
to   mature   IL-­1a   (88).   Additionally,   pro-­IL-­1a   and   pro-­IL-­1b   are   processed   into  
mature   cytokines   through   different   mechanisms.   Specifically,   pro-­IL-­1a   is  
processed  by  calpain  rather  than  caspase-­1  as  is  the  case  with  IL-­1b  (79,  89).    
In  human  disease,  IL-­1b  is  known  to  be  a  secreted  protein,  present  in  the  
blood,  and  is  not  present  in  the  serum  of  healthy  individuals  (90).  In  contrast,  IL-­
1a  is  contained  within  the  cytosol,  has  known  functions  under  normal  conditions,  
but   it   is  only  secreted  under  situations  of  damage  or   infection   (88).  Even  when  
released,  IL-­1a  typically  signals  in  an  autocrine  or  paracrine  fashion  and  is  rarely  
found  in  the  blood  except  for  in  cases  of  severe  infection  (91).  The  discovery  of  
this  secretion  pattern  made  it  one  of   the  first  “alarmins”   identified  and  has  been  
used   as   an   early   indicator   for   severe   infections   and   for   sepsis   (92).   Another  
characteristic  of  IL-­1a  which  is,  at  present,  underappreciated,  is  that  both  pro-­IL-­
1a  and  mature  IL-­1a  contain  an  active  nuclear   localization  signal   leading  to  the  
hypothesis  that  either  form  of  IL-­1a  could  act  as  a  transcription  factor  (84,  93).  This  
point,   is  critical   to  our  hypothesis  as   to   IL-­1a’s  potential  mechanism  (discussed  
later).    
Interestingly,  IL-­1a  has  a  unique  role  from  IL-­1b  within  the  central  nervous  
system.  In  the  brain,  polymorphisms  in  the  human  il1a  (but  not  il1b)  gene  result  in  
higher   incidence  of   vascular  malformation  and/or  higher   risk  of   ischemic  stroke  
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(94,  95).    This  strongly  suggests  that  the  two  isoforms  play  fundamentally  different  
roles  in  the  context  of  stroke.  Furthermore,  substantial  differences  in  the  spatio-­
temporal   expression   profile   of   IL-­1a   and   IL-­1b   occur   post-­stroke.   IL-­1a   is  
expressed  much  earlier  than  IL-­1b  after  stroke  onset  (4  h  versus  24  h  respectively),  
(83)   its   half-­life   is   also   significantly   longer   than   IL-­1b   (15   h   vs   2   h   half-­life,  
respectively)  (96)  in  and  around  areas  of  brain  injury,  and,  finally,  it  is  selectively  
expressed  in  microglia  acutely  (83).  
Although  IL-­1b  has  detrimental  effects  during  the  acute  phase  after  stroke,  
we   have   demonstrated   that   IL-­1a   induces   blood-­brain   barrier   (BBB)   repair,  
angiogenesis   and   neurogenesis   during   the   delayed   onset   of   injury   (76,   97).  
Furthermore,   we   have   previously   demonstrated   that   IL-­1a,   but   not   IL-­1b,  
selectively   triggers   angiogenesis   (an   important   component   of   post-­stroke  
neurorepair)   in   vitro   (98   (Chapter   3)),   and   increases   the   production   of  
neuroprotective  and  neuroreparative  (angiogenic  and  neurogenic)  perlecan  LG3  
(a   25-­kDa   protein   fragment   of   the   vascular   basement   membrane   component  
heparan  sulfate  proteoglycan  perlecan)  in  cells  of  the  neurovascular  unit  (99,  100).  
Importantly,  although  IL-­1a  has  been  implicated  in  promoting  angiogenesis  outside  
of  the  brain  (101),  we  are  the  first  to  suggest  its  potential  beneficial  role  in  post-­
stroke   angiogenesis   (98).   Likewise,   while   IL-­1b   has   been   shown   to   inhibit  
neurogenesis  in  the  adult  rodent  brain  (102,  103),  IL-­1a  has  been  demonstrated  
to   enhance   neurogenesis   of   bone   marrow-­derived   adult   human   mesenchymal  
stem  cells  in  vitro  (104).  
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Receptors  for  the  IL-­1  Family  
Prior  to  discussing  the  IL-­1  receptors,  it  is  important  to  discuss,  perhaps,  the  most  
important   member   of   the   IL-­1   signaling   complex:   the   interleukin-­1   receptor  
accessory  protein  (IL1RAcP).  While  IL1RAcP  shares  merely  25%  identity  with  IL-­
1R1  and  R2,   it   is  compulsory   for  any  IL-­1  mediated  signaling  to   take  place  and  
must  therefore  be  mentioned  within  this  discussion  (80,  81,  105,  106).  While  it  does  
not  bind  to  IL-­1  itself,  IL1RAcP  wraps  around  the  target  receptor  and  increases  the  
avidity  of  IL-­1  to  said  receptors  fivefold  (81,  107,  108).  The  IL-­1  family  of  cytokines  
can  bind  to  any  of  three  distinct  receptors:  aptly  named  IL-­1R1,2,  and  3.    
While  there  are  three  known  IL-­1  receptors,  IL-­1R1  is  the  most  common  and  the  
most  relevant  in  clinical  translation  of  stroke.  This  is  due,  in  part,  to  its  presence  as  
a  cell  surface  receptor  on  brain  vascular  endothelial  cells  and  will  be  discussed  in  
greater  detail  in  future  chapters  (19).  The  other  membrane  bound  receptor  is  IL-­
1R3  which  is  found  predominantly  on  neuronal  membranes.  Others  have  shown  
that  this  receptor  can  mediate  neuronal  survival  through  potassium  signaling  and  
through  the  prosurvival  Akt  pathway  (109).    
The  final  IL-­1  receptor  in  this  discussion,  IL-­1R2,  is  very  different  from  IL-­1R1  or  
R3.  It  not  an  active  receptor,  is  not  membrane  bound,  and  is  widely  thought  to  be  
a  decoy  receptor  due  to  its  ability  to  inhibit  IL-­1  signaling  (90).  Curiously,  while  IL-­
1b  is  not  present  in  the  serum  of  healthy  individuals,  IL-­1R2  is  ubiquitously  found  
within   the   serum   of   healthy   patients   (90,   110).   Additionally,   basal   IL-­1R2  
expression  is  significantly  higher  than  IL-­1R1  and  is  nearly  double  that  of  IL-­1RA,  
the  other  endogenous  inhibitor  of  IL-­1  signaling  (90).    
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IL-­1  in  Clinical  Practice  
The   final   member   of   the   IL-­1   family   is   IL-­1RA.   IL-­1RA   is   an   endogenous,  
competitive  inhibitor  of  the  IL-­1  receptor  1  (IL-­1R1)  (111).  IL-­1  blockade  has  been  
heavily  studied  in  a  number  of  systemic  human  diseases  as  well  as  those  within  
the  central  nervous  system  (112).  One  of  the  more  recent  anti-­inflammatory  clinical  
trials  aimed  at  blocking  the  IL-­1  receptor  using  IV  Anakinra,  a  IL-­1RA  type  drug  
approved  for  use  in  the  treatment  of  rheumatoid  arthritis  (66,  113).  Curiously,  all  
preclinical   data   has   been   obtained   using   IV   administration   of   IL-­1RA  while   the  
ONLY   approved   route   of   administration   (per   the  manufacturer’s   instructions)   is  
through  subcutaneous   injection.  While   this   is  unlikely   that   this   is   the   reason   for  
anakinra’s   clinical   failure   in   ischemic   stroke,   it   speaks   to   the   need   for   basic  
scientists   to   be   more   mindful   of   a   drug’s   translation   especially   using   an   FDA  
approved   drug   for   an   off-­label   use.   Pre-­clinical   studies   have   demonstrated   the  
deleterious  actions  of   IL-­1  after  stroke,  while  blocking   its  actions   is  beneficial   in  
pre-­clinical   (114)   and   clinical   (66)   settings.  While  most,   if   not   all,   studies   have  
focused  on  the  role  of  IL-­1b,  the  role  of  IL-­1a  during  post  stroke  inflammation  has  
been   overlooked   and   very   little   has   been   done   to   examine   the   selective  
contribution   of   each   IL-­1   isoform   in   ischemic   stroke   (91).   This   dissertation   is  
devoted   to   determining   the   selective   role   of   IL-­1a   in   stroke   as   a   beneficial  
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Stroke  remains  a  leading  cause  of  death  and  disability   in  the  United  States  and  
worldwide  despite  recent  breakthroughs  in  efforts  to  recanalize  occluded  vessels.  
Additionally,   many   clinical   trials   have   failed   despite   strong   preclinical   data.  
Recently,  combination  therapies  have  been  proposed  as  being  the  new  focus  for  
clinical  intervention  in  stroke.  T-­PA  is  often  given  in  conjunction  with  other  drugs  
as  well   as  with  endovascular   thrombectomy.  Our   lab  has   recently  developed  a  
model  of  intra-­arterial  drug  administration  after  thrombectomy.  We  now  show  that  
IL-­1a  is  an  excellent  contestant  drug  to  use  in  such  a  targeted  delivery  model.  We  
show   here   that,   while   IL-­1a   is   neuroprotective   when   given   systemically   (IV  
injection),   it   carries   transient   hemodynamic   side   effects   while   not   effecting  
systemic  markers  of  inflammation.  By  using  our  model  of  IA  drug  delivery,  we  no  
longer  see   these  side  effects  and  also  see  better  overall   outcomes.  This  study  
shows   that   intra-­arterial   drug   delivery   immediately   after   thrombectomy   could  
breathe   new   life   into   previously   discarded,   potentially   life-­saving  










Stroke  continues  to  be  a  leading  cause  of  death  and  long-­term  disability  worldwide  
(1).   While   the   advent   of   endovascular   thrombectomy   has   contributed   to   more  
patients  surviving  large  vessel  occlusion,  this  rising  number  of  stroke  survivors  has  
only  increased  the  need  for  effective  pharmacotherapies  for  post  stroke  recovery  
(115).  Among  many  other  post  stroke  pathways,  post-­ischemic  inflammation  has  
been   recognized   as   a   potential   area   for   potential   intervention   as   it   has   been  
identified  as  a  key  contributor  to  neuronal  injury  following  stroke  (9,  115).    
Generally,   post   ischemic   inflammation   is   characterized   by   the   expression   of  
inflammatory  mediators  by  activated,  immune  cells  within  the  core  of  the  infarct  (in  
the  brain  parenchyma),  such  as  microglia  and  astrocytes  (117).  This   leads   to  a  
general  activation  of  surrounding  cerebrovasculature  and  subsequent  opening  of  
the   BBB   resulting   in   edema   and   widespread   secondary   damage   by   peripheral  
immune  cells  (117).  More  recently,  this  invasion  of  peripheral  cells  has  been  shown  
to  contribute   to   long   term  neuroinflammation  as  well  as   to  post-­stroke  cognitive  
decline  (118).  Because  of  this  clear  and  present  need  for  drugs  to  ameliorate  this  
post-­stroke  inflammatory  injury,  many  preclinical  and  clinical  trials  have  examined  
the   use   of   anti-­inflammatory   therapeutics   (113).   Unfortunately,   attempts   at  
targeting   post   stroke   inflammation   have   failed   to   significantly   improve   patient  
prognosis  (112,  119).    
  
While   post–stroke   inflammation   is   certainly   to   blame   for   many   of   the   poor  
outcomes   following   stroke,   our   group   has   recently   described   the   action   of   pro-­
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inflammatory   cytokine,   interleukin-­1a,   as   a   potential   therapeutic   in   post-­stroke  
angiogenesis   in   vitro   (98).   We   are   now   able   to   show   that,   it   has   powerful  
neuroprotective  effects  when  given   immediately  upon   reperfusion.  Furthermore,  
we  have  recently  developed  a  model  of   intra-­arterial  (IA)  drug  delivery  following  
recanalization  of  occluded  vessels  (120,  121).  This  IA  model  of  drug  delivery  was  
designed  to  deliver  as  little  drug  as  possible  while  delivering  it  as  close  to  the  site  
of  stroke  injury  as  possible  (120).  This  is  in  an  effort  to  minimize  peripheral  effects  
of  peripherally  active  drugs;;  making  it  an  attractive  delivery  method  for  drugs  such  
as  IL-­1a  due  to  IL-­1a’s  known  action  as  a  fever  inducer  (122).  In  this  study,  we  
show   that   IL-­1a   is  hemodynamically  safe  and  profoundly  neuroprotective   in   the  
context  of  experimental  ischemic  stroke.  
  
Materials  and  Methods:  
IL-­1a  protein  preparation:    
Upon  arrival,  mouse   recombinant   IL-­1a   and   IL-­1b   (R&D  Systems,  Minneapolis,  
MN,  USA)  were  diluted  in  sterile  phosphate-­buffered  saline  containing  0.1%  low  
endotoxin  bovine  serum  albumin  (also  used  as  vehicle  control).  To  avoid  freeze  
thaw  cycles,  the  diluted  stock  solution  (50  ug/mL)  was  then  aliqotted  and  frozen  
for  dilution  to  the  desired  dose  on  the  day  of  surgery.    
  
Surgical  Methods:  
Tandem  Ipsilateral  Common  Carotid  and  Middle  Cerebral  Artery  Occlusion  Stroke  
Model    
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The  experimental  protocol  was  approved  by  the  Institutional  Animal  Care  and  Use  
Committee   of   the   University   of   Kentucky   and   experiments   were   performed   in  
accordance  with   the  Guide   for   the  Care  and  Use  of   Laboratory  Animals   of   the  
National   Institutes  of  Health  as  well  as   the  ARRIVE  guidelines.  Male  (3  months  
old)  C57/Bl6  mice  were  subjected  to  transient  tandem  ipsilateral  common  carotid  
artery   (CCA)/middle   cerebral   artery   (MCA)   occlusion   (MCAo)   for   60  min   (123),  
followed  by  reperfusion  of  both  arteries  for  up  to  7  days.    A  small  burr  hole  was  
made  in  the  skull  to  expose  the  MCA  and  a  metal  wire  with  a  diameter  of  0.005  
inch  was  placed  under  the  artery.    Slight  elevation  of  the  metal  wire  causes  visible  
occlusion   of   the   MCA.   The   CCA   was   then   isolated   and   occluded   using   an  
aneurysm  clip.    Diminished  blood  flow  was  confirmed  with  Laser  Doppler  Perfusion  
Monitor  (Perimed,  USA)  and  only  those  animals  with  a  diminished  blood  flow  of  at  
least  80%  and  re-­establishment  of  at  least  75%  of  baseline  levels  were  included  in  
subsequent  experimentation.    
  
Middle   Cerebral   Artery   Occlusion   Model:   3-­month-­old   mice   underwent   middle  
cerebral  artery  occlusion  as  previously  described  (123,  124).  Briefly,  mice  were  
anesthetized   and   their   external   carotid   artery   isolated   and   permanently   ligated  
distal   to   its   bifurcation   from   the   common   carotid   artery.   A   filament   was   then  
inserted  and  advanced  within  the  internal  carotid  artery  to  its  bifurcation  into  middle  
cerebral  artery.  The  filament  was  then  anchored  and  allowed  to  remain  there  for  
60  minutes.   The   filament  was   then   removed   and   the  ECA  permanently   ligated  
constituting  recanalization.    
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Intra-­arterial  drug  administration  of  IL-­1a:  Animals  in  the  IA  drug  delivery  cohort  
underwent  IA  drug  delivery  as  previously  described  (120).  Briefly,  the  mouse  was  
placed  in  a  supine  position  with  the  previously  isolated  CCA  exposed.  Following  
the  CCA  rostrally  to  its  bifurcation  point,  the  internal  and  external  carotid  arteries  
(ICA  and  ECA  respectively)  were  identified  and  three  lengths  of  6-­0  suture  were  
placed  under  the  ECA,  ensuring  its  isolation.  In  order  to  create  a  closed  system  to  
minimize  blood  loss,  one  of  the  sutures  was  used  to  ligate  the  ECA  distally  to  the  
bifurcation  while  a  microclamp  was  placed  on  the  ICA.  The  ECA  was  then  nicked  
just  proximally  to  the  ligation  point  and  the  drug  delivery  tubing  was  inserted  into  
the  nicked  vessel.  A  suture  was  used  to  secure  the  tubing  for  the  duration  of  drug  
delivery.   Once   the   tubing   was   successfully   placed,   the   mouse   underwent   the  
reperfusion  phase  of  the  tandem  ipsilateral  common  carotid  and  middle  cerebral  
artery  occlusion  stroke  model   (as  described  above),   the  clamp  on   the   ICA  was  
removed,   and   10-­25uL   drug   was   administered   at   a   rate   of   10uL   per   minute.  
Following  drug  administration,  a  suture  was  used  to  ligate  the  ECA  proximal  to  the  
nick  and  the  tubing  was  removed.  The  mouse  was  then  allowed  to  recover  for  the  
duration  of  the  study  (3  to  7  days).    
  
Treatment  with  IL-­1a:  Each  mouse  received  0.05  µg/kg  IL-­1a  (approximately  1  
ng  per  100µL  of  PBS)  via   tail  vein   (IV)   injection  or  0.005  µg/kg  via   IA   injection.  
Injections   were   performed   on   anesthetized   adult   mice   immediately   following  
recanalization  of  occluded  vessels.  All  mice  were   treated  on   the  day  of  surgery  
and  allowed  to  recover  until  PSD  3  or  7.    
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Blinding  and  Randomization:     
All  experiments  were  performed  in  a  blinded  and  randomized  fashion.  All  animals  
were  pre-­assigned  to  groups  (A,  B,  C  etc.)  using  an  online  randomization  website.  
Additionally,  other  personnel  were  tasked  with  making  up  the  drug  fresh  on  the  day  
of  use  and  labeling  them  with  the  correct,  blinded  identifier  as  described  above.  
The  primary  experimenter  was  not  unblinded  until  after  all  analysis  was  completed.  
  
Behavioral  Assessments:  
11-­point  Behavioral  Neurological  Score:  Mice  underwent  behavioral  assessment  
to  assess   the   following  behavioral  metrics:   level  of   consciousness   (LOC),  gaze  
(G),   visual   field   (VF),   sensorimotor   response   (SR),   and   grip   strength   and  
endurance/   paralysis   paw   hang   (PPH).   LOC   was   determined   prior   to   any  
disturbance  of  the  animal’s  cage  and  was  assessed  on  a  0-­2  severity  scale  with  0  
being  alert  and  active  without  outside  stimulus,  1  being  responsive  to  stimulus,  and  
2   being   huddled,   unresponsive,   and   non-­grooming.      Gaze   was   assessed   by  
passing   a   visual   stimulus   in   front   of   each   eye   in   turn  WITHOUT  disturbing   the  
mouse’s   whiskers.   The   subject   was   given   a   0   score   if   they   looked   toward   the  
stimulus  and  a  1  if  they  failed  to  do  so.  VF  was  assessed  by  holding  the  mouse  by  
the  tail  near  a  platform  (on  its  right  or  left  side)  and  if  the  mouse  reached  for  the  
platform  it  received  a  score  of  0.  If  it  did  not  reach  within  5  seconds,  it  was  given  a  
score  of  1  for  each  side  it  failed  on.  SR  was  scored  by  pressing  each  paw  in  turn  
to  elicit  a  reaction.  A  reaction  was  defined  as:  vocalizing  pain,  retracting  the  paw,  
or  jumping  in  response  to  the  paw  press.  A  lack  of  any  of  these  signs  resulted  in  a  
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score  of  1  for  each  paw  affected.  Finally,  PPH  was  scored  by  a  typical  paw  hang  
test.  The  mouse  uses  its  front  paws  to  hang  from  a  rod  for  a  period  of  60  seconds.  
The  mouse   receives   a   score   of   0   if   it   is   able   to   hang   with   both   paws   without  
dropping  a  paw  below  the  level  of  the  rod  for  the  full  60  seconds.  A  score  of  1  is  
earned  if  the  mouse  drops  either  paw  without  falling.  The  time  of  the  first  “partial”  
paw  drop  is  also  recorded.  A  score  of  2  is  earned  if  the  mouse  falls,  releasing  both  
paws,  at  any  time  during  the  60  second  time  period.  The  total  scores  are  tallied  at  
the  conclusion  of   the   testing   to  assess  overall   function.  Other  summary  metrics  
such   as   “latency   to   first   paw   drop”   were   also   used   to   help   assess   fine   motor  
function.  
Open  Field  Behavioral  Assessment:  Each  subject  was  placed  in  its  own  2x2  box  
and   tracked   using   the   EthoVision   12   software   for   5   minutes.   Animals   were  
assessed  on  the  day  prior  to  stroke  surgery,  and  then  again  on  PSD  1,  3,  and  7.    
Parameters  tracked  include  total  distance  traveled,  average  velocity,  turn  angle,  
and  time  spent  in  center  zone.  The  center  zone  was  defined  as  being  all  area  within  
the  box  that  was  at  lease  5  inches  away  from  the  walls  of  the  box.  This  parameter  
allowed  us  to  track  anxiety  as  a  function  of  how  long  the  animal  ventured  into  the  




Gross  cellular  morphology  was  assessed  using  Cresyl  Violet  staining.  Mounted  
sections  were  fixed  with  10%  phosphate  buffered  formalin.  They  were  then  stained  
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using  standard  Cresyl  Violet  staining  methods  with,  mounted  using  DPX  Mountant  
medium,  and  were  scanned  using  a  HP  Scanjet  G4050.  The  scanned  images  were  
analyzed  using  NIH  Image  J  for  infarct  volume  measurement  (123).  Infarct  regions  
were  defined  as  regions  with  hypodense  cresyl  violet  staining  reflecting  areas  of  
dead  or  dying  nuclei.  Areas  were  calculated  using  the  ImageJ  free-­hand  selection  
tool  and  summated  to  calculate  final  infarct  volume.  
  
TTC  staining.    
Upon  removal,  the  brain  was  placed  in  a  1mm  matrix  and  was  cut  into  2mm  coronal  
sections.   The   sections   were   submerged   in   a   1%   2,3,5   Triphenyltetrazolium  
chloride  (TTC)  solution  for  15  minutes.  They  were  then  removed  from  solution  and  
were  scanned  using  a  HP  Scanjet  G4050.  Normal,  healthy  tissue  turns  red  upon  
TTC’s  interaction  with  healthy  mitochondria.  Dead  and  dysfunctional  mitochondria  
remain  white  thus  highlighting  the   infarcted  region.  Areas  were  calculated  using  
the  ImageJ  free-­hand  selection  tool  and  summated  to  calculate  final  infarct  volume.  
  
Immunohistochemistry:    
Mounted,  20  um  tissue  sections  were  fixed  with  ice  cold  1:1  acetone:methanol  prior  
to  incubating  in  blocking  buffer  (5%  BSA  in  PBS  with  0.1%  Triton  X-­100)  for  one  
hour  at  room  temperature.    The  sections  were  then  incubated  overnight  at  4°C  in  
primary  antibody  (in  2%  BSA/0.1%  Triton  X-­100)  against  Ki67,  CD11b,  GFAP,  and  
NeuN.  Sections  were  washed  and  incubated  with  a  fluorescent  secondary  antibody  
(1:1000;;   AlexaFluor   488   or   568,   Life   Technologies)   for   one   hour   at   room  
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temperature.  Alternatively,  Milipore  ApopTag  staining  kits  were  used  as  directed  
to  stain  for  apoptotic  cells  with  a  TUNEL  marker.  Sections  were  washed  again  and  
then   coverslipped   with   fluorescent   mounting   media   containing   DAPI   (H-­1200,  
Vector  Labs)  and  images  were  captured  using  a  Nikon  Eclipse  Ti  microscope  and  
software   (Nikon).   Images   were   analyzed   for   antibody-­specific   positive   staining  
using  ImageJ  (threshold  pixel  intensity  made  similar  across  all  images  to  isolate  
antibody-­specific  staining  and  then  recorded  the  number  of  stain  positive  pixels).    
Results  are  from  3  sections  per  animal  and  the  area  selected  was  in  the  infarct  
core  identified  morphologically.  
  
Statistical  Analysis:  All  experiments  were  performed  in  duplicated  studies,  and  
each  treatment  group  contained  at  least  4  mice.  Data  are  represented  as  mean  ±  
SE   of   the  mean   (SEM).   Comparison   between   two   groups  was   done   using   the  
Student’s  t-­test.  Comparison  between  three  or  more  groups  was  performed  using  
one-­way  ANOVA  followed  by  a  Tukey’s  post  hoc  analysis.  For  CXCL1  and  IL-­6  
ELISA  assays,  data  were  analyzed  by  two-­way  ANOVA  and  Bonferroni  post  hoc  
test.  Significance  was  determined  by  a  p  value  of  <  0.05.  
  
Results:  
IL-­1a  is  directly  protective  of  primary  cortical  neurons  after  OGD  in  vitro  
As  a  proof  of  concept,  we  first  aimed  to  show  that  IL-­1a  could  impart  protection  to  
neurons   undergoing   an   in   vitro   stroke   analogue   such   as   oxygen   glucose  
deprivation  (OGD).  Our  original  hypothesis  was  that  IL-­1a  worked  through  another  
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cell   type   (astrocytes   or   endothelia)   to   impart   protection.   To   test   this,   primary  
cortical  neurons  from  E18  mouse  pups  were  plated  on  sterile  coverslips  and,  after  
a   week,   underwent   OGD   or   normoxia   for   30  minutes.   Reperfusion  media   was  
conditioned  with  either  PBS  vehicle  or  varying  concentrations  of  IL-­1a  (0.01,  1,  10,  
and  100  ng/mL).  After  24  hours   reperfusion,  we  stained   the  cells  with  Hoechst  
nuclear   stain   for   30   minutes   and   then   fixed   and   mounted   (125).   Cells   were  
visualized   on   a   Nikon   inverted   microscope   and   quantified   for   chromatin  
fragmentation   and   cellular   health.   Cells   were   classified   as   being   healthy   or  
unhealthy  (125).  We  quantified  5  areas  per  coverslip  or  up  to  200  healthy  cells  with  
9  coverslips  per   treatment  group  (Figure  2.1).  We  found  that   IL-­1a  significantly  
increased  the  cell  viability  after  OGD  (Figure  2.1A)  (57.20  ±  2.05%  viability  with  
vehicle  treatment  vs  83.45  ±  0.98%  with  1ng/mL  IL-­1a  treatment)  and  after  20µM  
NMDA  insult  (Figure  2.1B).  Interestingly,  although  not  surprisingly,  the  lowest  and  
highest  doses  were  not  as  beneficial  (0.01  ng/mL:  77.72  ±  1.84%)  and,  in  fact,  the  
highest  doses  were  detrimental  even  under  normoxic  conditions  (100  ng/mL  IL-­1a  
under   normoxia:   64.73   ±   2.43%   vs   60.68   ±   1.47%   under   OGD).   What   was  
surprising,  was   that   IL-­1a  was  directly  protective  of  a  relatively   fragile  cell   type.  
This   supports   the   idea   that   IL-­1a,   being   a   cytokine,   is   still   a   viable   therapeutic  
option  under  appropriate  dosing  regimens.  Data  represent  mean  ±  SEM.  n=9.    
  
IL-­1a  reduces  infarct  volume  and  apoptotic  cell  death  following  stroke.  
In   order   to   show   that   IL-­1a   could   be   an   attractive   therapeutic   target   following  
stroke,  we  first  wanted  to  demonstrate   its  efficacy  at  preventing  ischemic  injury.  
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We  also  wanted  to  show  that  IL-­1a  was  an  attractive  candidate  for  IA  drug  delivery  
using   our   model   (120).   At   7   days   after   stroke,   animals   which   received   IL-­1a  
showed   significantly   lower   levels   of   apoptotic   cell   death   on   TUNEL   staining  
(Figures  2.2A  and  2.2B)  (vehicle:  14047  ±  1469  vs  IV  IL-­1a:  3093  ±  466.2  TUNEL  
positive  pixels)  as  well  as   lower  overall   infarct  volumes  on  cresyl  violet  staining  
(Figure  2.2C)  (vehicle:  21.93  ±  2.75  mm3  vs  IV  IL-­1a:  (3.546  ±  0.72  mm3  vs  IA  IL-­
1a:  4.664  ±  0.72  mm3).  Interestingly,  while  IA  IL-­1a  administration  did  not  lessen  
overall  infarct  volumes  compared  with  IV  IL-­1a  administration,  IA  IL-­1a  appears  to  
decrease   apoptotic   cell   death   compared   to   IV   IL-­1a   although   this   effect   is   not  
statistically  significant  (IV  IL-­1a:  3093  ±  466.2  vs  441.7  ±  152.2  TUNEL  positive  
pixels  p  =  0.1708).  Data  represent  mean  ±  SEM.  n=10  for  infarct  volume  and  n=3  
for  TUNEL  stains.  
  
IL-­1a  reduces  intraparenchymal  inflammatory  activation  after  stroke.  
We   next   wanted   to   see   if   IL-­1a,   being   a   pro-­inflammatory   cytokine,   instigated  
widespread  inflammatory  activation  within  the  brain.  Unsurprisingly,  we  saw  that  
stroked   animals   had   widespread   microglial   (CD11b)   activation   (21556   ±   3903  
positive  pixels)   (Figure  2.3A  and  2.3B).  What  did  surprise  us  was  that  animals  
receiving  IV  IL-­1a  showed  decreased  CD11b  staining  compared  to  control  (9098  
±  1580  positive  pixels).  Additionally,  animals  which  received  IA  IL-­1a  showed  even  
less  CD11b  staining  compared  to  IV  IL-­1a  (1952  ±  611.2  positive  pixels).  These  
data  suggest  that,  contrary  to  conventional  wisdom,  the  administration  of  low  dose  
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IL-­1a  could  actually  decrease  the  inflammatory  response  to  stroke.  Data  represent  
mean  ±  SEM.  n=5  
  
IL-­1a  improves  functional  outcomes  following  stroke.  
In  order  to  solidify  IL-­1a  as  an  attractive  post  stroke  therapeutic  target,  we  aimed  
to  show  that  these  IL-­1a  treated  animals  received  functional  benefit  compared  to  
their  PBS  treated  counterparts  upon  behavioral  testing.  Mice  underwent  a  battery  
of  behavioral   tests  (which  we  compiled   into  an  11-­point  neurological  score)  and  
open   field   testing.  While   there   were   no   significant   differences   in   our   compiled  
behavioral  score  (data  not  shown),  upon  open  field  testing,  we  found  that  both  IV  
and  IA  treated  animals  traveled  farther  in  overall  distance  than  their  vehicle  control  
counterparts  on  both  PSD  1  (Two  Way  ANOVA  *p<0.05  vehicle:  1762.07  ±  157.86  
cm  vs  IV  IL-­1a:  2797.45    ±  318.49  cm  vs  IA  IL-­1a:  2633.04  ±  431.55  cm)  and  PSD  
7  (Two  Way  ANOVA  **p<0.01  vehicle:  1587.41  ±  209.70  cm  vs  IV  IL-­1a:  2849.18    
±  347.31  cm  vs  IA  IL-­1a:  2994.12  ±  248.34)  cm  (Figure  2.4).  Additionally  we  noted  
that  animals  in  both  IV  and  IA  treated  groups  spent  more  time  in  the  open  areas  of  
the  arena  rather  than  staying  near  the  walls  (data  not  shown).  This  suggests  that  
these   animals   are   both   more   mobile   and   are   not   exhibiting   elevated   anxiety  
compared   to   controls.   Even   more   interestingly,   these   effects   become   more  
pronounced   with   increased   time   after   stroke.   Taken   together,   we   found   that,  
regardless   of   treatment   modality,   acute   IL-­1a   treatment   improves   functional  
outcomes  after  stroke.  Data  represent  mean  ±  SEM.  n  =  5.  
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IL-­1a  treatment  is  safe  up  to  200,000x  its  effective  dose.  
It  has  long  been  established  that  IL-­1a  is  an  early  mediator  of  fever  and  an  early  
signaling  molecule  in  sepsis.  Our  published   in  vitro  research  (shown  in  Chapter  
3),  as  well  as  the  study  above,  demonstrated  that,  at   low  doses,  we  can  induce  
reparative   processes   in   endothelial   cells   (98)   and   direct   protection   of   primary  
neurons  (Figure  2.1).  In  this  experiment,  we  wanted  to  identify  the  dose  at  which  
IL-­1a  becomes  unsafe  in  mice.  We  defined  this  threshold  based  on  the  findings  of  
(126)  et  al  who  defined  fever  in  a  mouse  to  be  1  C°  sustained  increase  in  body  
temperature.  We  went  on  to  classify  that  increase  as  a  “mild”  fever  and  classified  
2.5  or  more  degrees  C  sustained  increase  in  body  temperature  as  being  a  severe  
fever.   In  animals  that  underwent  MCAo  surgery,  we  administered  5,  7.5  and  10  
mg/kg  of  IL-­1a  via  tail  vein  injection  and  monitored  core  body  temperature  by  rectal  
probe   (along  with   other   vital   statistics   such   as   heart   rate   and   pulse   distension  
which  is  analogous  to  blood  pressure  in  mice).  None  of  the  mice  who  received  5  
mg/kg  developed  fever.  50%  of  the  mice  who  received  7.5  mg/kg  developed  fever  
with  at  least  1  of  them  developing  severe  fever.  Finally,  75%  of  the  mice  receiving  
10  mg/kg   developed   fever   with   all   classified   as   having   sustained   severe   fever  
(Figure  2.5)  This  suggests  that  even  if  we  increased  our  chosen  dose  105-­fold,  it  






IL-­1a  treatment  does  not  elevate  systemic  proinflammatory  mediators  in  serum.  
In   order   to   compare   the   systemic   benefit   of   the   IA   drug   delivery   method,   we  
evaluated   levels   of   known   proinflammatory   cytokines   in   the   serum   of   mice  
recovering  from  stroke  and  IL-­1a  treated  animals.  To  do  this,  we  obtained  serum  
from   stroked   and   treated   animals   24   hours   post   stroke   and   then   again   upon  
sacrifice  at  PSD  7  to  evaluate  if  there  was  significant  elevation  of  proinflammatory  
cytokines  in  the  serum  in  response  to  not  only  the  stroke,  but  also  in  response  to  
IL-­1a  injection.  We  found  that,  contrary  to  our  hypothesis,  none  of  the  cytokines  
evaluated  showed  any  significant  elevation  (Figure  2.6  A-­C)  and  further  supports  
the  previous  data   showing   that   IL-­1a   is   systemically   safe  using  our  model   and  
dosage  (Figure  2.5)  (At  PSD  1,  IL-­1b:  p  =  0.6408;;  IL-­6:  p  =  0.9332;;  and  CXCL-­1:  
p  =  0.6462)  n  =  4  
  
Perlecan  plays  an  important  role  in  IL-­1a  mediated  neuroprotection  after  stroke.  
Finally,  we  wanted  to  determine  the  mechanism  by  which  IL-­1a  could  be  working.  
Our   past   work   suggested   that   elements   of   the   extracellular   matrix,   such   as  
perlecan,  are  broken  down  after   stroke  and   that   this  process  could  partially  be  
driven  by  IL-­1a  (99).  Additionally,  we  know  that  one  of  these  proteolytic  fragments,  
perlecan   LG3,   is   neuroprotective   following   OGD.   In   order   to   see   whether   this  
protection  is  translated  in  mice,  we  used  a  mouse  with  truncated  perlecan,  that  is,  
perlecan  lacking  the  LG3  fragment  (pln  -­/-­).  Interestingly,  while  WT  mice  exhibited  
neuroprotection  following  IL-­1a  treatment  (One-­Way  ANOVA  ****p<0.0001  infarct  
volume  WT  vehicle:  18.99  ±  2.50  mm3  vs  WT  IL-­1a:  3.65  ±  0.8921  mm3),  pln  -­/-­  
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mice  did  not  gain  the  same  neuroprotection  after  IL-­1a  treatment  (infarct  volume  
pln  KO  vehicle:  23.38  ±  1.99  mm3  vs  pln  KO  IL-­1a:  26.36  ±  3.50  mm3).  This  shows  
that  IL-­1a  requires  the  LG3  fragment  of  perlecan  in  order  to  impart  neuroprotection  














Figure  2.1  IL-­1a  conveys  direct  neuroprotection  in  vitro.  Primary  cortical  neurons  
under  two  forms  of  cytotoxic  stress  (A)  OGD  or  (B)  20µM  NMDA.  Excess  IL-­1a  
concentrations   are   cytotoxic   while   moderate   doses   conveyed   direct   protection  
from  oxygen-­glucose  deprivation  (OGD)  as  well  as  NMDA  based  toxicity.  Data  are  
the  mean  ±  SEM  (n  =  9  per  group).  
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Figure  2.2   IL-­1a   treatment   reduces  cellular  apoptosis  and   infarct  volume.  Mice  
treated  with  IA  IL-­1a  have  (A)   fewer  apoptotic  cells   in   the   infarct  and  periinfarct  
regions  than  vehicle  and  IV  IL-­1a  treated  mice  (B)  Quantification  of  TUNEL  and  
(C)  cresyl  violet  stains.  Mice  treated  with  IA  IL-­1a  have  reduced  infarct  volumes  





















Figure  2.3  Mice  treated  with  IA  IL-­1a   less  microglial  activation   in  the  periinfarct  
regions  than  vehicle  or   IV  IL-­1a   treated  mice.  Representative   images  of  CD11b  
(green)  staining  showing  less  overall  microglial  staining  in  the  periinfarct  region  of  
treated  animals  compared  to  controls  (B)  Quantification  of  CD11b  stains.  Data  are  
the  mean  ±  SEM  (n  =  4  per  group).    *p  <  0.05  ***p  <  0.001  Scale  =  200μm.  





















Figure   2.4   IL-­1a   enhances   functional   recovery   following   stroke.   Mice   were  
evaluated  for  functional  performance  by  using  total  distance  traveled  in  an  open  
field  free  movement  paradigm.  Mice  were  evaluated  for  a  baseline  measurement  
the  day  prior  to  stroke  surgery  and  then  evaluated  for  functional  recovery  on  PSD  
1  and  PSD  7.  Mice  treated  with  IA  or  IV  IL-­1a  show  better  functional  outcome  than  






























Figure   2.5   Larger   doses   of   IL-­1a   are   not   protective   and   induce   negative   side  
effects.  Larger  doses  of  IV  IL-­1a  can  cause  (A)  fever,  (B)  elevated  heart  rate,  and  
(C)   elevated   pulse   distension.   Additionally,   IL-­1a   is   no   longer   protective   at   the  
larger   doses   as  measured   by   (D)   infarct   volume   calculated   using   cresyl   violet  





































































































inflammatory  mediators  after  stroke.  IL-­1a  administered  IV  (1ng)  or  IA  (0.1ng)  had  
no  effect  of  systemic  (blood)  levels  of  (A)  TNF-­a,  (B)  IL-­6  and  (C)  CXCL1  24h  after  
MCAo,  compared  to  vehicle-­treated  and  sham  control  animals.  Data  are  the  mean  























Figure  2.7  Pln  KO  animals  are  resistant  to  IL-­1a-­mediated  protection.  Mice  lacking  
the  LG3  fragment  of  perlecan  do  not  sustain  the  same  IL-­1a-­mediated  protection  
showing   larger   infarct   volumes   overall   than   WT   controls   (A).   Quantification   of  

























infarct  volumes  obtained  from  cresyl  violet  stains  (B)  (One-­Way  ANOVA  ####  p  
<0.0001  WT  IL-­1a  vs  pln  KO  IL-­1a;;  ****p  <  0.0001  WT  PBS  vs  WT  IL-­1a)  Data  are  























We  set  out   to  show  that   IL-­1a   is  an  attractive   therapeutic   target   for  post  stroke  
intervention.  Stuart  Allan’s  group  in  Manchester,  England  has  definitively  shown  
that  IL-­1a  is  one  of  the  first  cytokines  upregulated  after  stroke  (83).  We  recently  
showed  that  IL-­1a  treatment  of  endothelial  cells  showed  benefit  in  vitro  (98).  We,  
therefore,  reasoned  that  a  cytokine,  present  so  early  in  stroke  injury  progression,  
could  be  a  prominent  player   in   infarct  evolution  and  could  even  be  beneficial   to  
cortical   neurons.   We   found   that   under   OGD   conditions   IL-­1a   imparted  
neuroprotection  onto  primary  cortical  neurons.  More  interesting,  was  the  fact  that  
IL-­1a  was  protective  only  under  certain  doses.  The  highest  doses  and  lower  doses  
were  not  significantly  protective  and,  in  the  case  of  the  highest  dose  of  100ng/mL,  
the  IL-­1a  was  neurotoxic.  This  told  us  that  we  would  need  to  find  which  doses  of  
IL-­1a  treatment  which  would  be  detrimental  (or  even  lethal)  in  vivo  and  compare  
that  dose  to  the  doses  that  have  been  used  by  other  groups  as  well  as  by  our  own  
group.    
In  order  to  confirm  that  the  previously  established  dose  of  ~0.05  µg/kg  was  safe,  
we  originally  set  out  to  find  IL-­1a’s  LD50  in  mice.  Interestingly,  our  highest  dose,  10  
mg/kg,  which  was  105  times  greater  than  the  established  dose  was  not  lethal.  This  
shifted  our  focus  to  seeing  whether  any  of  the  doses  tested  resulted  in  negative  
side  effects.      IL-­1a   is  a  known  mediator  of   fever  and  so  we  chose  fever  as  our  
warning  symptom  (122).  As  described  above,  we  found  that  7.5  mg/kg  produced  
50%  fever  out  to  at  least  30  minutes  following  recanalization.    While  none  of  these  
mice  died  during  or  after  the  injections,  these  results  clearly  show  that  the  IL-­1a  
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that  we  injected  was  both  active  and  could,  at  high  enough  doses,  produce  severe  
fever  as  well  as  other  hemodynamic  changes  such  as  blood  pressure  and  heart  
rate.  These  symptoms  are  dangerous  enough  to  exclude  it  as  a  potential  therapy.  
It  was  therefore  important  to  us  to  verify  these  “danger”  thresholds  in  our  studies  
to  both  show  that  our  chosen  therapeutic  dose  was  safe  and  to  show  just  how  far  
removed   our   dose   is   compared   to   those   doses   which   produce   negative   side  
effects.  
After   showing   that   our   established   dose  was   safe,  we   proceeded   to   show   that  
treating  mice  with  IL-­1a    is  neuroprotective.  We  showed  that  even  though  our  dose  
does  not  produce  severe  fever  or  major  complications,  systemic  administration  (IV  
injection)  of   IL-­1a  does   result   in   transient,  mild  hemodynamic  changes  such  as  
fleeting  changes  in  pulse  distension  (analogous  to  blood  pressure)  and  heart  rate.  
Our  intra-­arterial  model  of  drug  delivery  gave  us  the  opportunity  to  administer  less  
IL-­1a,   thereby   lessening   the  chance  of   inducing   the  side  effects  outlined  above  
(121).  It  also  allowed  us  to  deliver  the  IL-­1a  nearly  directly  to  the  location  of  the  
stroke.  Additionally,  since  it  is  known  that  IL-­1a   is  transported  across  the  blood-­
brain  barrier  (BBB)  (96),  we  were  able  to  be  reasonably  confident  that  most  of  our  
drug  was   taken  up   into   the  brain  parenchyma   rather   than  being  metabolized   in  
systemic   circulation.  While  we   know   that   IL-­1a   is   transported   (96)   and  we   are  
confident  that  our  drug  is  taken  up  into  the  brain,  this  is  an  area  which  is  actively  
being  pursued  in  the  lab.    
Perhaps   most   importantly,   IL-­1a   facilitates   functional   recovery   and   decreases  
neuroinflammatory  activation  particularly  when  it  is  delivered  IA.  There  are  a  few  
	  51	  
potential  reasons  for  this  reduction  in  neuroinflammation.  First,  we  are  giving  less  
drug  and  so  any  potential  inflammatory  activation  caused  by  the  introduction  of  a  
cytokine   is   reduced  compared   to  our   IV  dose.  Second,   IL-­1a   could  be  working  
through  another  mechanism  of  neuroprotection  thereby  reducing  the  inflammatory  
response   secondary   to   smaller   overall   injury.   Finally,   IL-­1a   could   be   working  
through  a  negative  feedback  loop  to  reduce  inflammatory  cell  activation.  This  could  
be  in  part  through  its  interaction  with  the  BBB  and  perlecan’s  generation  of  LG3.  
Naturally,  a  combination  of  these  reasons  is  likely  plausible,  however,  more  studies  
will  need  to  be  done  in  order  to  parse  out  which  potential  reason  for  the  observed  
reduction  in  inflammation  is  most  correct.  
Taken  together,  we  were  able  to  use  IL-­1a  and  our  recently  developed  model  as  
a  proof  of  concept  for  giving  potentially  life-­saving  drugs  using  a  safer  drug  delivery  
mechanism.  Our  stroke  model  produces  infarcts  that  are  similar  to  those  resulting  
from  large  vessel  occlusions  in  the  clinic  (123).  Endovascular  thrombectomy  gives  
clinicians  a  great  opportunity   to  deliver  drugs   in  a   targeted   fashion   immediately  
following   vessel   recanalization   (120).  Our   IA   drug   delivery  method  models   this  
targeted   drug   delivery   very   closely   (120).   This   is   a   chance   for   drugs   to   be  
reexamined  as  post  stroke  therapeutics  that  have  been  previously  discarded  on  







Taken   together,   our   studies   have   shown   that   IL-­1a   is   an   attractive   therapeutic  
target  for  neuroprotective  intervention  after  experimental  ischemic  stroke.  We  have  
shown  that  IL-­1a  is  directly  neuroprotective   in  vitro  and  that  it  is  neuroprotective  
when  given   IV  or   IA   (with   IA  delivery   imparting  even  greater  benefit)  potentially  
through   perlecan   releasing   LG3.   We   believe   that   IL-­1a   combined   with  
endovascular  thrombectomy  could  represent  a  new  avenue  for  stroke  treatment  
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Inflammation  is  a  major  contributor  to  neuronal  injury  and  is  associated  with  poor  
outcome  after  acute  brain   injury  such  as  stroke.  The  pro-­inflammatory  cytokine  
interleukin   (IL)-­1   is   a   critical   regulator   of   cerebrovascular   inflammation   after  
ischemic  injury,  mainly  through  action  of  both  of  its  isoforms,  IL-­1a  and  IL-­1b ,  at  
the   brain   endothelium.   In   contrast,   the   differential   action   of   these   ligands   on  
endothelial  activation  and  post-­stroke  angiogenesis  is  largely  unknown.  Here  we  
demonstrate  that  IL-­1a  is  chronically  elevated  in  the  brain  after  experimental  stroke  
suggesting  that  it  is  present  during  post-­stroke  angiogenic  periods.  Furthermore,  
we   demonstrate   that   IL-­1a   is   a   potent   mediator   of   endothelial   activation   and  
inducer  of  angiogenic  markers  in  endothelial  cells  in  vitro.  Using  brain  endothelial  
cell  lines,  we  found  that  IL-­1a was  significantly  more  potent  than  IL-­1b  at  inducing  
endothelial   cell   activation,   as   measured   by   expression   of   the   pro-­angiogenic  
chemokine   CXCL-­1.   IL-­1a   also   induced   strong   expression   of   the   angiogenic  
mediator  IL-­6   in  a  concentration-­dependent  manner.  Furthermore  IL-­1a   induced  
significant  proliferation  and  migration  of  endothelial  cells,  and  promoted  formation  
of  tube-­like  structures  that  are  established  key  hallmarks  of  angiogenesis  in  vitro.  
Finally,  all  of  those  responses  were  blocked  by  the  IL-­1  receptor  antagonist  (IL-­
1RA).  In  conclusion,  our  data  highlights  a  potential  new  role  for  IL-­1  in  brain  repair  
mechanisms  and  identifies  IL-­1a  as  a  potential  new  therapy  to  promote  post-­stroke  
angiogenesis.  




Inflammation   is  a  key  host  defense   response   to   infection  and   injury,   the  aim  of  
which  is  host  protection  against  pathogens,  regeneration  of  injured  tissues  and  re-­
establishment  of  tissue  homeostasis  (127).  It  is  now  recognized  that  inflammation  
is   also  a   key   contributor   to   neuronal   ischemic   injury   that   occurs   after   stroke,   a  
leading  cause  of  death  and  morbidity  worldwide  with   limited  therapeutic  options  
(115).   This   inflammatory   response   after   cerebral   ischemia   has   long   been  
considered  detrimental  and  due  to  its  slowly  evolving  nature,  has  been  identified  
as  a  potential  therapeutic  target  in  acute  ischemic  stroke  (116).  Inflammation  after  
cerebral   ischemia   is   characterized   by   central   expression   of   inflammatory  
mediators,  activation  of  the  local  innate  immune  cells  of  the  brain,  activation  of  the  
brain  cerebrovasculature  and  subsequent  opening  of  the  blood-­brain  barrier  (BBB)  
that  allows  for  edema  and  circulating  immune  factors  into  the  brain  parenchyma,  
contributing  to  secondary  brain  damage  (19).  A  key  mediator  of  inflammation  after  
cerebral   ischemia   is   the   pro-­inflammatory   cytokine   interleukin-­1   (IL-­1)   (116).  
Microglia,  astrocytes  and  endothelial  cells  express  both  of  the  IL-­1  isoforms,  IL-­1a  
and  IL-­1b,  after  cerebral  ischemia  (122),  and  both  cytokines  contribute  to  neuronal  
injury  by  acting  primarily  on  endothelial  cells  and  astrocytes  (128).  IL-­1  action  at  
the  cerebrovasculature  is  considered  a  primary  trigger  of  post  stroke  inflammation  
(83),   and   may   represent   a   therapeutic   target   (114).   Although   IL-­1-­driven  
inflammation  is  detrimental  during  the  acute  phase  of  ischemic  injury,  inflammation  
also  exerts  beneficial  effects  by  promoting  brain  repair  mechanisms  and  functional  
recovery;;  Indeed,  IL-­1  induces  generation  of  LG3  in  brain  cell  cultures,  a  potentially  
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neuroprotective   and   pro-­angiogenic   protein   fragment   of   the   extracellular-­matrix  
component  perlecan  (99,  100).  Furthermore,  IL-­1  induces  central  expression  of  the  
acute   phase   protein   pentraxin-­3,   a   key   regulator   of   repair   mechanisms   after  
cerebral   ischemia,   including  glial  scar   formation,  BBB  integrity  and  resolution  of  
edema  (76),  as  well  as  neurogenesis  and  angiogenesis  (97).  Although  IL-­1-­driven  
repair  mechanisms  at  the  cerebrovasculature  are  gradually  being  unravelled,  the  
potential  role  of  IL-­1  as  a  direct  regulator  of  angiogenesis  after  ischemic  injury  is  
completely  unknown.  Importantly,  we  have  demonstrated  a  selective  role  for  IL-­1a  
(but  not  IL-­1b)  in  activating  endothelial  cells  to  produce  LG3  (99),  and  although  IL-­
1a   has   been   reported   to   exert   pro-­angiogenic   effects   during   peripheral  
inflammation   (101,   129),   the   potential   role   of   IL-­1a   on   brain   angiogenesis   has  
never  been  explored.  Using  cultured  brain  endothelial  cells,  we  demonstrate  for  
the   first   time   that   IL-­1a   induces   several   stages   of   angiogenesis   as   well   as  
expression   of   key   pro-­angiogenic   markers   in   brain   endothelial   cells   in   vitro,  
highlighting  the   important  role  of  angiogenesis  driven  by  IL-­1a  during  the  repair  
phase  after  acute  CNS  inflammatory  conditions.  
  
MATERIALS  AND  METHODS  
Tandem  Ipsilateral  Common  Carotid  and  Middle  Cerebral  Artery  Occlusion  Stroke  
Model    
The  experimental  protocol  was  approved  by  the  Institutional  Animal  Care  and  Use  
Committee   of   the   University   of   Kentucky   and   experiments   were   performed   in  
accordance  with   the  Guide   for   the  Care  and  Use  of   Laboratory  Animals   of   the  
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National   Institutes  of  Health  as  well  as   the  ARRIVE  guidelines.  Male  (3  months  
old)  C57/Bl6  mice  were  subjected  to  transient  tandem  ipsilateral  common  carotid  
artery   (CCA)/middle   cerebral   artery   (MCA)   occlusion   (MCAo)   for   60  min   (123),  
followed  by  reperfusion  of  both  arteries  for  up  to  7  days.    A  small  burr  hole  was  
made  in  the  skull  to  expose  the  MCA  and  a  metal  wire  with  a  diameter  of  0.005  
inch  was  placed  under  the  artery.    Slight  elevation  of  the  metal  wire  causes  visible  
occlusion   of   the   MCA.   The   CCA   was   then   isolated   and   occluded   using   an  
aneurysm  clip.    Diminished  blood  flow  was  confirmed  with  Laser  Doppler  Perfusion  
Monitor  (Perimed,  USA)  and  only  those  animals  with  a  diminished  blood  flow  of  at  
least  80%  and  re-­establishment  of  at  least  75%  of  baseline  levels  were  included  in  
subsequent  experimentation.    
  
Preparation  of  brain  lysates  
Mice  were  transcardially  perfused  with  0.9%  NaCl,  and  brains  were  extracted  and  
homogenised   in   buffer   (50mmol/L   Tris-­HCl   pH   7.4,   150mmol/L   NaCl,   5mmol/L  
CaCl2,   0.02%   NaN3,   1%   Triton-­X)   containing   protease   inhibitors.   After  
centrifugation   (17,000   g   for   30   min),   supernatants   were   collected   and   protein  
concentrations   calculated   by   bicinchoninic   acid   protein   assay   (Thermo-­Fisher  
Scientific,  UK).  Protein   concentration  was   adjusted   to   1  mg/mL   for   all   samples  





Endothelial  cell  cultures  
Brain  microvascular  endothelial  cells   (BECs)   from  C57BL/6  mice  maintained  as  
cells   lines   (124,   130),   and   the  mouse  bEnd.5   cell   line   (which   closely   resemble  
primary   brain   endothelial   cells),   were   used   in   this   study.   C57BL/6   BECs   were  
cultured  on  porcine  gelatin-­coated  tissue  culture  plates  (unless  stated  otherwise)  
in   Iscove’s   Modified   Dulbecco’s   Medium   (IMDM)   containing   10%   fetal   bovine  
serum  (FBS),  1  U/mL  penicillin,  100  mg/mL  streptomycin  and  1%  L-­glutamine,  and  
were  kept  at  37°C  and  5%  CO2.  bEnd.5  were  cultured  in  Dulbecco’s  modified  Eagle  
medium  (DMEM)  (high  glucose,  4.5  g/L;;  Invitrogen,  Paisley,  UK),  supplemented  
with  10%  FBS,  1%  nonessential  amino  acid,  2  mM  glutamine,  1  U/mL  penicillin,  
and  100  mg/mL  streptomycin,  and  were  kept  at  37°C  and  5%  CO2.    
  
Cell  treatments  
Mouse   recombinant   IL-­1a  and   IL-­1b   (R&D  Systems,  UK)  were  diluted   in  sterile  
phosphate   buffered   saline   (PBS)   containing   0.1%   low   endotoxin   bovine   serum  
albumin  (BSA)  (also  used  as  vehicle  control).    Cultures  were  treated  with  vehicle,  
IL-­1a  or  IL-­1b  (0.1  –  100  ng/mL)  (based  on  the  known  biological  activity  of  IL-­1a  
(99)  in  the  presence  or  absence  of  IL-­1RA  (Kineret:  Lot#  26458  IF)  (10  µg/mL)  for  
5   h   (CXCL-­1   release),   6   h   (for   chemotaxis   chamber   and   Tube-­like   Structure  





Measurement   of   CXCL1,   IL-­1a,   and   IL-­6   release   by   enzyme-­linked  
immunosorbent  assay  (ELISA)  
Levels  of  CXCL1,  and  IL-­6  levels  in  the  culture  media  or  IL-­1a  in  brain  lysates  were  
quantified   using  DuoSet®  mouse  CXCL1/CINC-­1,  mouse   IL-­1a,   or  mouse   IL-­6  
ELISAs,  respectively,  according  to  the  manufacturer’s  instructions  (R&D  Systems,  
UK).  The  detection  limits  of  the  assay  were  47  pg/mL  for  CXCL1,  23  pg/mL  for  IL-­
6,  and  16  pg/mL  for  IL-­1a.  Levels  for  all  cytokines  analyzed  were  expressed  as  
pg/mL.  
  
Cellular  proliferation  assay  assessed  by  MTS  
BECs   were   seeded   on   uncoated   tissue   culture   plates   at   a   density   of   10,000  
cells/cm2  in  96-­well  plates  in  IMDM  containing  10%  FBS.  After  24  h,  the  media  was  
changed  to  IMDM  containing  1%  FBS  and  cytokine  treatment  conditions.  After  24  
h,  MTS  reagent  (Cell  titer96;;  Promega,  Madison,  WI,  USA)  was  added  to  each  well  
and  the  absorbance  was  read  at  1,  1.5  and  2-­h  time  points  at  490  nm.  Data  were  
reported  as  a  percentage  of  the  control  conditions.  
  
  
Cellular  proliferation  assay  measured  by  cell  count  
24-­well  plates  were  coated  with  porcine  gelatin   for  20  min  prior   to  cell  seeding.  
BECs  were  seeded  at  5,000  cells/cm2  in  IMDM  containing  10%  FBS.  After  24  h,  
the   media   was   changed   to   IMDM   containing   1%   FBS.   After   treatments   with  
cytokines  for  24  h,  the  conditioned  media  was  collected  and  250  µL  trypsin  was  
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added  to  each  well  and  allowed  to  incubate  for  5  min.  500  µL  1%  FBS-­containing  
IMDM  was  then  added  to  each  well  to  inactivate  the  trypsin.  The  detached  cells  
were  then  transferred  to  1.5  mL  microcentrifuge  tubes  and  spun  at  1,000  rpm  for  
5  min  at  room  temperature.  The  media  was  removed  and  the  pellet  was  then  re-­
suspended  in  50  µL  of  1%  FBS-­containing  media.  The  cells  were  then  counted  on  
a  hemocytometer  using  a  1:2  dilution  with  Trypan  Blue.  Data  were  expressed  as  
cells   counted   on   hemocytometer   and   reported   as   percentage   of   the   control  
conditions.    
  
Scratch  migration  assay  
BECs  were  seeded  at  a  density  of  10,500  cells/cm2  and  grown  for  48  h  in  10  %  
FBS-­containing  IMDM,  after  which  the  cell  layer  was  scratched  mechanically  with  
a   200µL   pipet   tip.   The   culture   medium   was   then   removed   and   new   media  
containing  1  %  FBS  was  added.  After   treatments  with  cytokines  for  24  h,  bright  
field   microscopic   pictures   of   the   scratches   were   taken,   and   the   area   of   the  
remaining,  unfiled  scratch  was  measured  using   ImageJ  Software.  Results  were  
expressed  as  a  percent  of  the  scratch  filled/repaired  by  the  cell  monolayer.  Data  
were  expressed  as  percentage  of  scratch  area  filled.  
  
Chemotactic  migration  assay  
Poycarbonate  membranes  (Neuro  Probe,  Inc.,  USA)  with  8  µm  pores  were  coated  
with  100  µg/mL  Collagen  Type  I  (Corning;;  USA)  in  0.02N  acetic  acid  overnight  at  
4°C.  The  bottom  wells  of  a  Chemotaxis  Chamber  (Neuro  Probe,  USA)  contained  
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chemotactic  controls  (0  and  1%  serum  media)  and  treatment  conditions  (IL-­1a  ±  
IL-­1RA).  After  assembly  of  the  chamber  as  per  the  manufacturer’s  instructions,  the  
upper  wells  were  seeded  at  15,000  cells/well  in  0%  serum  media  or  10  µg/mL  IL-­
1RA  conditions  and  the  chamber  was  incubated  at  37°C  for  6  h.  The  cells  on  the  
underside  of  the  membrane  were  fixed  in  methanol  and  stained  with  crystal  violet  
(0.5%).   The   membrane   was   then   cut   into   sections,   mounted   on   a   slide,   and  
visualized.  Upon  visualization,  migrated  cells  were  counted  and  recorded.  Results  
were   expressed   as   mean   number   of   cells   that   migrated   to   the   bottom   of   the  
membrane  as  a  percentage  of  the  serum  starved  (control)  condition.  
  
Matrigel  tube-­like  morphology  assays  
Slow  thawed  growth  factor  reduced  Matrigel   (Corning,  USA)  was  coated  on  the  
wells  of  a  24-­well  plates  (35µL  per  well)  for  1  h  37°C  for  1  h.  Cells  were  passaged  
into  their  diluted  concentrations  in  IMDM  supplemented  with  1%  serum,  as  well  as  
cytokine  treatment  conditions  and  were  incubated  at  37°C  for  20  min.  Cells  were  
seeded  at  15,000  cells/cm2and  allowed  on  the  Matrigel  for  6  h  at  37°C  before  being  
fixed  with  4%  paraformaldehyde  at   4°C  overnight.  Pictures  were   taken  using  a  
Nikon   Eclipse   Ti   Microsoft   camera   using   Nikon   software.   Using   the   ImageJ  
software,  hyper-­reflective  borders  of  capillary-­like  structures  were  quantified  using  
a   consistent   threshold.  Results  were   expressed  as  mean  percentage  of   hyper-­





All  experiments  were  performed  on  at  least  three  independent  cultures,  and  each  
condition  was  performed  in  triplicate.  Data  are  represented  as  mean  ±  standard  
error  of   the  mean  (SEM).  Comparison  between  two  groups  was  done  using  the  
Student’s  t-­test.  Comparison  between  three  or  more  groups  was  performed  using  
one-­way   ANOVA   followed   by   a   Tukey   post-­hoc   analysis.   For   CXCL1   and   IL-­6  
ELISA  assays,  data  were  analyzed  by  2-­way  ANOVA  and  Bonferroni  post-­hoc  test.  
Significance  was  determined  by  a  p  value  of  less  than  0.05.  
  
RESULTS  
IL-­1a  is  elevated  in  the  mouse  brain  after  experimental  ischemic  stroke  
In  order   to   investigate  whether   IL-­1a  was  expressed   in   the  brain  after  stroke   to  
potentially  play  a  role  in  post  stroke  recovery,  we  analyzed  brains  of  stroked  mice  
at  several  time  points  relative  to  the  initiation  (post-­stroke  day  3)  and  maintenance  
(post-­stroke  day  7)  of  post-­stroke  angiogenesis.    We  found  that  while  IL-­1a  levels  
remain  comparable  to  sham  animals  at  post-­stroke  day  3,  after  7  days  IL-­1a  levels  
were  significantly  elevated  (Figure  3.2).  This  demonstrates  that  IL-­1a  is  elevated  
in  the  brain  days  after  experimental  stroke  and  could  be  a  significant  mediator  of  
chronic  post  stroke  processes.    
IL-­1a  increases  brain  endothelial  cell  activation  
In  order  to  determine  the  differential  potency  by  which  IL-­1α  and  IL-­1β  might  trigger  
pro-­angiogenic   responses   in   BEC   cultures,   we   first   investigated   the   effect   of  
recombinant  IL-­1α  or  IL-­1β  on  expression  of  CXCL1,  a  chemokine  expressed  upon  
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endothelial  cell  activation  and  known  to  play  a  key  role  in  recruitment  of  immune  
cells  into  the  brain  after  acute  injury  (131)  and  to  exert  angiogenic  actions  (132,  
133).  Both   IL-­1a   and   IL-­1b   induced  marked   increased  expression  of  CXCL1   in  
BECs,  and   increased  expression  was  concentration-­dependent   for  both   ligands  
(Figure   3.3A).   Interestingly,   optimum   concentration   of   cytokines   that   induced  
maximum  CXCL1  expression  was  found  to  be  1  ng/mL  for  both  IL-­1a  and  IL-­1b,  
while  a  plateau  was  reached  for  the  concentrations  of  10  and  100  ng/mL.  For  all  
the  concentrations  tested,  IL-­1a  was  more  potent  than  IL-­1b  at  inducing  CXCL1  
expression,  and  this  differential  expression  was  significant  for  the  concentrations  
of  1-­100  ng/mL.  Given   these  results,  all  of   the   following  experiments   tested   the  
effect  of  IL-­1a  only.  IL-­1a  -­induced  CXCL1  expression  was  completely  inhibited  by  
co-­incubation  with  IL-­1RA  (Figure  3.3B),  while  IL-­1RA  alone  had  no  effect  (data  
not  shown)  demonstrating  that  these  effects  were  mediated  by  the  IL-­1  receptor  
type  1  (IL-­1R1).  Finally,  IL-­1a  induced  significant  release  of  IL-­6  (known  to  exert  
angiogenic   actions   in   brain   endothelial   cells   (134,   135))   in   a   concentration-­
dependent  manner,  with  optimum  concentration  of   IL-­1a   found  to  be  10  ng/mL,  
while  a  plateau  was  reached  for   the  concentration  of  100  ng/mL  (Figure  3.3C).  
These  results  demonstrate  that  IL-­1a  is  a  potent  activator  of  BECs,  and  since  both  
CXCL1  and   IL-­6  have  been  previously   reported   to  mediate  angiogenesis   (132-­
135),   these   results   suggest   that   IL-­1a   might   trigger   angiogenic   responses   in  




IL-­1a  increases  proliferation  of  endothelial  cells  
We   next   investigated   whether   IL-­1a   could   affect   BEC   proliferation,   a   known  
hallmark  of  endothelial  angiogenic  response  in  vitro,  as  measured  directly  by  cell  
counts   and   indirectly   by  MTS  assay.  Visualisation   of   cultures   using   bright   field  
microscopy  found  that  IL-­1a  triggered  cellular  proliferation  which  was  blocked  by  
IL-­1RA,  but  also  demonstrated   that  no  cytotoxicity  occurred   in   response  of  any  
treatments  (Figure  3.3A).  We  found  that  IL-­1a  (10  ng/mL  or  50  ng/mL)  increased  
cellular  proliferation  compared  to  untreated  (1%  serum  control)  cultures,  which  was  
inhibited  by  IL-­1RA  (Figure  3.3B);;  Quantification  of  cellular  proliferation  showed  
that  10  ng/mL  IL-­1a  significantly  increased  endothelial  proliferation  by  nearly  two-­
fold  while  50  ng/mL   IL-­1a  also   increased  endothelial  proliferation,  although   this  
was  not  significant.  Cellular  proliferation  in  response  to  both  IL-­1a  concentrations  
tested  was  significantly  blocked  by  IL-­1RA.  Interestingly,  IL-­1RA  alone  appeared  
to  significantly  inhibit  basal  endothelial  proliferation,  suggesting  that  endogenous  
IL-­1a  actions  might  be  involved.    
Similarly,   we   found   that   IL-­1a   significantly   increased   endothelial   proliferation  
compared  to  vehicle  treatment,  as  measured  by  MTS  assay  (111.0  ±  3.528%  for  
10  ng/mL,  112.8  ±  4.278%  for  50  ng/mL)  (Figure  3.3C).  We  also  found  that  the  
addition  IL-­1RA  decreased  IL-­1a  -­induced  endothelial  proliferation,  while  IL-­1RA  
alone  had  no  effect.  Collectively,  these  results  indicate  that  IL-­1a  increases  BEC  




IL-­1a  increases  BEC  migration  
We   next   investigated   the   potential   effect   of   IL-­1a   on   BEC   migration,   another  
hallmark   of   angiogenic   responses   in   endothelial   cells,   using   scratch   and  
chemotactic  migration  assays.  In  the  scratch  assay,  which  measures  cell  migration  
into  a  “scratch”  wound,  10  ng/mL  or  50  ng/mL  IL-­1a  significantly  increases  BEC  
migration  into  the  wound  (1.70-­fold  increase  for  10  ng/mL  and  1.65-­fold  increase  
for  50  ng/mL  respectively)   (Figure  3.5A  and  B).   IL-­1RA  blocked   IL-­1a   induced  
endothelial  cell  migration,  although  this  was  only  significant  for  the  concentration  
of  10  ng/mL  of  IL-­1a,  while  IL-­1RA  alone  had  no  effect.  
In  order  to  confirm  the  potential  effect  of  IL-­1a  to  induce  chemotactic  migration  in  
BECs,   we   performed   chemotaxis   chamber   migration   assays   in   which   serum-­
starved   cells  migrate   towards   1%   serum   across   a   porous  membrane.   Vehicle-­
treatment   triggered  a  moderate   increase   in  chemotaxic  migration  of  endothelial  
cells   (Figure   3.5C).   However,   IL-­1a   (10   ng/mL   and   50   ng/mL)   significantly  
increased   the   number   of   cells   that   migrate   compared   to   1%   serum-­directed  
controls.  Finally,   IL-­1RA  significantly   blocked   the  pro-­migratory   activity   of   IL-­1a  
indicating   that   IL-­1a   promotes   chemotactic   migration   of   BECs   in   an   IL-­1R1-­
mediated  fashion.    
  
IL-­1a  promotes  formation  of  capillary  tube-­like  structures  
Finally,  we   investigated  whether   IL-­1a  enhances  capillary  morphogenesis  using  
the  Matrigel  assay,  another  stage  of  angiogenesis.   Indeed,   IL-­1a  enhanced   the  
formation  of  capillary  tube-­like  structures  (2.45  fold  for  10  ng/mL  and  1.44-­fold  for  
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50  ng/mL)  (Figure  3.6).  This  effect  was  inhibited  by  IL-­1RA,  while  IL-­1RA  alone  
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Figure  3.2:   IL-­1a   is  chronically  elevated  after  experimental  stroke   in  mice.  
Lysates  from  the  brains  of  3-­month-­old  male  C57Bl6  mice  and  their  sham  controls  
were  collected  at  3  and  7  days  after  experimental  stroke  and  assayed  for  IL-­1a  by  
ELISA.  IL-­1a  was  significantly  elevated  at  7  days  post  stroke  compared  to  day  7  

































































































































Figure  3.3:   IL-­1a   induces  expression  of  CXCL-­1  and   IL-­6   in  BECs.  Lysates  
from  Bend.5  endothelial  cells,  treated  as  labelled,  were  collected  and  assayed  for  
CXCL-­1  (A  and  B)  and  IL-­6  (C)  by  ELISA.  All  cytokines  were  significantly  increased  
in   cultures   treated  with   IL-­1a   and   demonstrated   a   greater   increase   than   IL-­1b.  
Additionally,  this  effect  was  blocked  in  the  presence  of  IL-­1RA.  *p<0.05,  **p<0.01,  




















Figure   3.4:   IL-­1a   increases   proliferation   of   BECs.  Trypan   blue   stained  C57  
BECs,  treated  for  24  h  as  labelled,  were  counted  with  a  hemocytometer  24  h  after  
treatment   (A   and   B).   Scale   bar   is   200   microns.   C.   Spectrophotometric   MTS  
readings  after  60,  90  and  120  min  for  cells,  treated  as  labelled.  Numbers  represent  
the  percent  proliferation  as  compared  to  1%  serum  control  conditions.  *p<0.05  vs.  
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Figure  3.5:    IL-­1a  increases  migration  of  BECs.  Monolayers  of  C57  BECs  were  
scratched  and  treated  as  labelled  at  the  time  of  wounding.  The  area  of  the  scratch  
was  analysed  and  graphed  as  the  percent  of  the  wound  filled  in  by  the  cells  (shown  
in  A,  quantified  in  B).  Scale  bar  is  200  microns.  Quantification  of  chemotaxis  assay  
showed  increases  in  both  the  1%  serum  and  IL-­1α  conditions.  *p<0.05,  **p<0.01,  







Vehicle       -          +         +        +         +        +         +  
IL-1α (10ng/mL)       -          -          +        +         -         -          - 
IL-1α (50ng/mL)     -           -         -          -         +        +          -



























Vehicle                      +          +           +          +           +          +
IL-1α (10ng/mL)      -           +           +          -            -          -      
IL-1α (50ng/mL)      -            -            -          +           +           -





















 IL-1α with 
10µg/mL IL-1RA 
50ng/mL 
























Figure   3.6:      IL-­1a   increases   BEC   capillary-­tube   like   morphogenesis   on  
Matrigel  Matrix.    A.  Images  of  C57  BECs  on  Matrigel  for  6  h,  treated  as  labelled.  
Arrows   indicate  some  of   the  capillary   tube-­like  structures   that  were   formed.     B.  
Graph  represents  the  %  of  capillary-­tube-­like  positive  pixels  per  high-­powered  field  
after   6   hours   of   treatment   as   labelled.   Scale   bar   is   200   microns.   **p<0.01,  
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Angiogenesis  is  an  important  component  of  post-­stroke  repair  that  may  aid  in  the  
restoration  of  blood  flow  to  ischemic  brain  regions  and  generate  a  neurovascular  
niche  to  guide  and  support  neurogenesis  (75).  In  this  study,  we  found  that  IL-­1a  is  
significantly   elevated   even   a   week   after   experimental   stroke.   Since   IL-­1   is   an  
important   inflammatory   mediator   known   to   trigger   post-­stroke   inflammation   by  
acting   primarily   on   endothelial   cells   (99),   and   IL-­1a   has   been   suggested   to  
selectively   act   on   endothelial   cells   to   exert   neuroprotective   and   pro-­angiogenic  
effects  (100),  we  investigated  the  potential  of  IL-­1a  to  enhance  brain  angiogenesis  
in   vitro.  Such  pro-­angiogenic  activity,   combined  with  our  observation  of   chronic  
expression  of  IL-­1a  after  experimental  stroke,  would  support  the  hypothesis  that  
IL-­1α  could  be  a  key  driver  of  brain  post-­ischemic  injury  angiogenesis  and  thereby  
represents  a  novel  stroke  therapeutic  target.  Our  results  demonstrated  that  IL-­1a  
enhances   key   stages   of   angiogenesis,   including   endothelial   activation,  
proliferation,  migration  and  capillary  morphogenesis,  and  induces  important  pro-­
angiogenic  mediators  (CXCL1  and  IL-­6)  in  an  IL-­1R1-­dependent  manner;;  First,  we  
found  that  IL-­1a  was  chronically  elevated  in  the  stroked  brain.  Next,  we  found  that  
both  IL-­1a  and  IL-­1b  induced  strong  activation  of  endothelial  cells,  measured  by  
expression  of  the  chemokine  CXCL1,  although  the  effect  of  IL-­1a  was  significantly  
higher  to  that  of  IL-­1b,  confirming  the  observations  of  our  previous  study  (99)  and  
that  of  others  (96,  136,  137)  that  IL-­1a  acts  as  a  selective  activator  of  endothelial  
cells.   Importantly,   although   CXCL1   is   known   for   its   chemotaxis   functions,   this  
chemokine   has   been   reported   to   have   potent   pro-­angiogenic   actions.   Indeed,  
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CXCL1  is  known  to  induce  angiogenesis  in  peripheral  endothelial  cells  (138),  and  
the  angiogenic  actions  of  prostaglandin  E2  is  mediated  by  CXCL1  in  disease  (139).  
Finally,   CXCL1   has   been   reported   to   promote   angiogenesis   by   expressing  
neutrophil-­derived  vascular  endothelial  growth  factor  (VEGF)  (139)  adding  to  our  
hypothesis  that  IL-­1a  could  mediate  angiogenesis  in  the  brain.  This  hypothesis  is  
further  supported  by  the  fact  that  IL-­1a  induces  strong  expression  of  the  cytokine  
IL-­6,  an  established  pro-­angiogenic  mediator  in  the  CNS.  Indeed,  IL-­6  is  known  to  
promote  post-­traumatic   repair   in   the  CNS   (140)  and   induces  vasculogenesis  of  
brain  microvessel  endothelial  cells  (141).  Surprisingly,  our  data  found  that,  while  
IL-­1a   induces   strong   IL-­6   expression   in   endothelial   cells,   it   failed   to   induce  
expression   of   VEGF   (data   not   shown).   However,   IL-­6   is   known   to   induce  
expression  of  VEGF  in  astrocytes  (142).  These  observations  taken  together  with  
our  data  suggest  that  IL-­1a  could  exert  pro-­angiogenic  effects,  at  least  in  part,  by  
inducing  IL-­6  expression  in  endothelia,  which  in  turns  may  activate  neighbouring  
perivascular  astrocytes  that  produce  VEGF  to  subsequently  induce  angiogenesis.  
The  potential  significance  of  IL-­6  in  the  pro-­angiogenic  effects  of  IL-­1a  is  actively  
being  investigated.      
In  further  support  of  our  hypothesis  that  IL-­1a  has  pro-­angiogenic  actions  on  brain  
endothelial   cells,   we   found   that   IL-­1a   induced   strong   BEC   proliferation   and  
migration,  and  promoted  formation  of  tube-­like  structures,  which  are  key  features  
of   angiogenesis   and   established   angiogenic   assay   in   vitro.   Interestingly,   in   our  
BEC  migration  experiments,  we  noted  that  IL-­1α  both  stimulated  migration  into  a  
scratch  wound  and  acted  as  a  migration  chemotactant,  which  let  us  speculate  that  
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IL-­1a  expressed  after  ischemic  injury  by  peri-­infarct  astrocytes,  microglia  and  other  
endothelial  cells  (99),   like  other  angiogenic/chemotactant  factors  such  as  VEGF  
and  angiopoetin,  attracts  migrating/angiogenic  endothelial  cells.  Additionally,  we  
found  that  IL-­1R1  blockade  with  IL-­1RA  in  the  absence  of  IL-­1a  was  sufficient  to  
blunt   some   baseline   angiogenic   responses   (proliferation   and   migration),  
suggesting   that   endogenously   generated   IL-­1a   may   exert   some   angiogenic  
effects,  further  supporting  the  role  of  IL-­1a  in  brain  angiogenesis.    
While   our   data   suggest   that   CXCL1   and   IL-­6   could   mediate   IL-­1α-­induced  
angiogenesis,  other  mediators  might  be  involved.  Indeed,  one  possibility  is  that  IL-­
1a  enhances  angiogenesis  via  causing  brain  endothelial  cells  to  generate  the  pro-­
angiogenic  extracellular  matrix  fragment  perlecan  LG3,  as  we  have  demonstrated  
in  our  previous  studies  (99).  In  the  same  study,  we  demonstrated  that  IL-­1β  did  not  
exert  this  effect  and  in  contrast,  decreased  LG3  levels  below  baseline  levels  (99,  
124),   further  distinguishing  the  selective  effects  IL-­1a  on  brain  endothelial  cells.  
Current  studies  to  ascertain  the  mechanism(s)  by  which  IL-­1a  generates  LG3  and  
whether  this  could  be  responsible,  at  least  in  part,  for  its  angiogenic  effects,  are  
ongoing.  
Another  important  caveat  to  this  study  is  that  it  was  performed  almost  entirely  in  
vitro  using  murine  rather  human  cells  and  cell  lines  rather  than  primary  cells.  The  
potential  role  of  IL-­1a  in  brain  angiogenesis  in  vivo  is  currently  under  investigation  
in  our   laboratory.  Furthermore,  while   the  current  study  demonstrates   that   IL-­1a  
promotes   brain   angiogenesis   in   vitro   under   normal   conditions   (normoxia   and  
normoglycemia),  further  studies  are  necessary  to  determine  the  experimental  and  
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therapeutic  relevance  of  IL-­1a  as  a  key  driver  of  brain  angiogenesis  after  ischemic  
injury.    For  example,  IL-­1a  dose-­response  and  variable  dosing  schedule  studies  in  
experimental   stroke   could   be   performed   to   determine   IL-­1a’s   safety   and  
(angiogenic)   therapeutic   efficacy.   Furthermore,   while   IL-­1RA   is   currently   being  
considered  as  an  anti-­inflammatory  therapeutic  approach  targeting  the  detrimental  
acute   phase   of   inflammation   (114),   our   results   highlight   the   possibility   that  
sustained   IL-­1a   levels   might   be   important   to   promote   key   repair   mechanisms  
including   angiogenesis.   Indeed,   our   study   suggests   that   refined   IL-­1RA  
administration  (time  window  and  amount  to  be  administered)  might  be  necessary  
or  that  selective  inhibition  of  IL-­1β  to  favour  the  potentially  more  beneficial  effects  
of  IL-­1α  could  be  achieved  by  co-­administering  IL-­1RA  followed  by  chronic  low  IL-­
1a  regimens.        
  
Conclusion:  
In  summary,  the  present  study  demonstrates  that  the  inflammatory  cytokine  IL-­1a  
enhances   several   stages   of   brain   angiogenesis   in   vitro   in   a   receptor-­mediated  
fashion.    This  novel  observation  adds  further  support  to  the  idea  that  inflammatory  
signals   in   the  brain,  such  as   those   that  occur  after  stroke,  may  exert  beneficial  
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A  primary  event  in  stroke  pathogenesis  is  the  development  of  a  potent  local  and  
peripheral   inflammatory   response   known   to   contribute   to   poor   outcome   and  
impaired  functional  recovery.  Whilst  acute  inflammation  is  known  for  its  deleterious  
effect  after  stroke,  the  role  of  subacute  (delayed  inflammation)  in  mechanisms  of  
brain   repair   and   functional   recovery   is   unclear.   Inflammation   after   stroke   is  
regulated  by  the  pro-­inflammatory  cytokine  interleukin-­1,  and  whilst  the  role  of  IL-­
1b  (main  release  isoform)  in  stroke  pathogenesis  has  been  largely  studied,  the  role  
of  IL-­1a  (main  intracellular  isoform)  remains  largely  unknown.    We  have  recently  
reported   that   IL-­1a   is   significantly   more   potent   than   IL-­1b   at   inducing   brain  
endothelia  cell  activation  and  proliferation,  and  expression  of  endothelial  markers  
of  angiogenesis  in  vitro.  Here  we  show  for  the  first  time  that  IL-­1a  administration  
at  low  sub-­pathological  doses  during  the  subacute  period  following  experimental  
stroke   (induced   by   middle   cerebral   artery   occlusion)   induces   less   brain   tissue  
damage,   promotes   angiogenesis   and   ameliorates   functional   recovery   while  
inducing  minimal  physiological  adverse  effect.  Our  present  study  suggests  for  the  
first  time  that  exogenous  manipulation  of  subacute  chronic  IL-­1a  levels  could  be  








Stroke   is   a   leading   cause   of   death   and   disability   worldwide,   and   despite   the  
promise   of   many   potential   neuroprotective   therapies,   none   have   thus   far  
succeeded  in  clinical  trials  (115).  While  the  speed  and  efficacy  of  recanalization  
(using   tissue   plasminogen   activator   or  mechanical   clot   removal)   has   improved,  
patients   continue   to   experience   poor   outcome   and   functional   recovery   is   often  
limited  (121).  Brain  damage  after  stroke  is  triggered  by  the  primary  ischemic  injury  
causing   rapid   neuronal   cell   death,   followed   by   reperfusion   injury   triggered   by  
recanalization  of  the  occluded  blood  vessel,  excitotoxicity,  reactive  oxygen  species  
formation,  and  subsequently  inflammation.  The  role  of  inflammation  driven  by  the  
pro-­inflammatory  cytokine  interleukin  (IL)-­1  during  post-­stroke  injury  has  been  the  
focus   of   intense   research   (126,   143).   Indeed,   pre-­clinical   studies   have  
demonstrated  the  deleterious  actions  of  IL-­1  after  stroke,  while  blocking  its  actions  
is  beneficial  in  pre-­clinical  (114)  and  clinical  (112)  settings.  The  large  majority  of  
studies   have   focused   on   the   role   of   IL-­1beta   (b)   (main   released   isoform),   and  
demonstrated   that   IL-­1b   is   a   primary   mediator   of   central   and   peripheral  
inflammation   after   stroke   (93)   and   many   preclinical   studies   have   focused   on  
modifying   IL-­1b   levels   (by   exogenous   administration   of   recombinant   IL-­1b or  
selective   anti-­IL-­1b   neutralizing   antibodies   on   experimental   ischemia   in   rodent  
models  (84).    However  the  role  of  IL-­1alpha  (a)  (main  intracellular  isoform)  during  
post   stroke   inflammation   is   largely   unknown,   but   recent   published   works   have  
demonstrated  marked  differences  between  mechanisms  of  expression  and  action  
of  these  two  cytokines,  suggesting  that  IL-­1a  might  exert  specific  actions;;  IL-­1b  is  
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the  main  secreted  isoform,  whereas  IL-­1a  generally  remains  cytoplasmic,  but  can  
also  be  released  during  cell  death  or  by  mechanisms  that  are  different  from  that  of  
IL-­1b  (93),  and  several  previous  studies  have  demonstrated  differential  actions  of  
both  cytokines  in  various  paradigms  of  inflammation  (144).  In  stroke,  brain  IL-­1a  
expression  precedes  that  of  IL-­1b  and  occurs  predominantly  in  microglia  localized  
to   focal   neuronal   and   BBB   injury   in   this   acute   period   (83).   Furthermore,  
polymorphisms   in   the   human   il1alpha   but   not   il1beta   gene   result   in   higher  
incidence  of  vascular  malformation  and/or  higher  risk  of  ischemic  stroke  (94,  95),  
suggesting  that  IL-­1a  may  exert  different  actions,  possibly  during  the  acute  phase  
of  ischemic  injury.  Importantly  our  previously  published  report  demonstrated  that  
IL-­1a   is   significantly   more   potent   than   IL-­1b   at   inducing   brain   endothelial   cell  
activation  and  proliferation,  and  triggered  key  hallmarks  of  angiogenesis  in  in  vitro,  
which   could   have   important   implications   during   neuroregenerative   repair  
mechanisms  after   ischemic   injury   (98).  The  present  study  extends  our  previous  
findings   and   demonstrate   for   the   first   time   that   exogenous   intravenous  
administration  of  subpathological  doses  of   IL-­1a   is  highly  neuroprotective  when  
injected  during  the  acute  phase  of  injury,  and  enhances  post-­stroke  angiogenesis  
when  injected  during  the  sub-­acute  phase  of  ischemic  injury.  Our  results  have  very  
important   implications  by  proposing   for   the   first   time   that   complete   inhibition  of  
post-­stroke  neuroinflammation  may  have  detrimental  effects,  whilst  sustaining  low  
grade  chronic  inflammation  might  be  used  as  new  effective  therapy  for  brain  tissue  
repair  and  functional  recovery  after  stroke.  
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Materials  and  Methods:    
Recombinant  IL-­1a  protein  preparation:    
Mouse  recombinant  IL-­1a  and  IL-­1b  (R&D  Systems,  Minneapolis,  MN,  USA)  were  
diluted  in  sterile  phosphate-­buffered  saline  containing  0.1%  low  endotoxin  bovine  
serum  albumin   (also  used  as  vehicle  control).  To  avoid   freeze   thaw  cycles,   the  
diluted  stock  solution  (50  ug/mL)  was  then  aliquoted  and  frozen  for  dilution  to  the  
desired  dose  on  the  day  of  surgery.    
  
Surgical  Methods:  
Experimental  protocols  were  approved  by  the  Institutional  Animal  Care  and  Use  
Committee  of   the  University  of  Kentucky,  as  well  as  the  Home  Office  (UK),  and  
experiments  were  performed  in  accordance  with  the  Guide  for  the  Care  and  Use  
of  Laboratory  Animals  of  the  National  Institutes  of  Health  as  well  as  the  ARRIVE  
guidelines  
  
Tandem   ipsilateral  common  carotid  and  middle  cerebral  artery  occlusion  stroke  
model    
Male  (3  months  old)  C57/Bl6  mice  were  subjected  to  transient  tandem  ipsilateral  
common  carotid  artery  (CCA)/middle  cerebral  artery  (MCA)  occlusion  (MCAo)  for  
60  min  (123),  followed  by  reperfusion  of  both  arteries  for  up  to  7  days.    A  small  
burr   hole   was  made   in   the   skull   to   expose   the  MCA   and   a   metal   wire   with   a  
diameter  of  0.005  inch  was  placed  under  the  artery.    Slight  elevation  of  the  metal  
wire   causes   visible   occlusion   of   the   MCA.   The   CCA   was   then   isolated   and  
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occluded  using  an  aneurysm  clip.    Diminished  blood  flow  was  confirmed  with  Laser  
Doppler   Perfusion   Monitor   (Perimed,   USA)   and   only   those   animals   with   a  
diminished   blood   flow   of   at   least   80%  and   re-­establishment   of   at   least   75%  of  
baseline  levels  were  included  in  subsequent  experimentation.    
  
Middle   Cerebral   Artery   Occlusion   Model:   3-­month-­old   mice   underwent   middle  
cerebral   artery   occlusion   (MCAo)   as   previously   described   protocol   (123,   124).  
Briefly,   a   hole   was  made   into   the   temporalis  muscle   (6  mm   lateral   and   2  mm  
posterior  from  bregma)  to  allow  a  0.5  mm  diameter  flexible  laser-­Doppler  probe  to  
be   fixed   onto   the   skull   and   secured   in   place   by   tissue   adhesive   (Vetbond).   A  
midline  incision  was  made  on  the  ventral  surface  of  the  neck  and  the  right  common  
carotid  artery  isolated  and  ligated.  Topical  anaesthetic  (EMLA,  5%  prilocaine  and  
lidocaine,  AstraZeneca,  UK)  was  applied  to  skin  incision  sites  prior  to  incision.  The  
internal  carotid  artery  and  the  pterygopalatine  artery  were  temporarily  ligated.  A  6-­
0  monofilament  (Doccol,  Sharon,  MA,  USA)  was  introduced  into  the  internal  carotid  
artery  via  an   incision   in   the  common  carotid  artery.  The  filament  was  advanced  
approximately   10  mm  distal   to   the   carotid   bifurcation,   beyond   the   origin   of   the  
middle  cerebral  artery.  Relative  CBF  was  monitored  for  the  first  30-­45  min  following  
MCAo,   during   which   time   relative   CBF   had   to   reduce   by   at   least   70%   of   pre-­
ischemic  values  for  inclusion.  After  30  min  of  occlusion,  the  filament  was  withdrawn  
back  into  the  common  carotid  artery  to  allow  reperfusion  to  take  place.  The  wound  
was  sutured  and  mice  received  a  subcutaneous  bolus  dose  of  saline  for  hydration  
(500   µl)   and   a   general   analgesic   (Buprenorphin   e,   0.05   mg/kg   injected  
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subcutaneously).   Animals   were   kept   at   26-­28°C   until   they   recovered   from  
anaesthesia   and   surgery,   before   being   transferred   back   to   ventilated   cages  
suspended   over   a   heating   pad  with   free   access   to  mashed   food   and  water   in  
normal  housing  conditions.  
  
Treatment  with  IL-­1a:  Each  mouse  received  0.05  mg/kg  IL-­1a  (approximately  1  
ng  per  100uL  of  PBS)  via  tail  vein  (IV)  injection.  Injections  were  performed  on  un-­
anesthetized  adult  mice  using  a  mouse  restrainer  to  avoid  confounding  affects  with  
anesthesia.  For  single  injection  studies,  all  mice  were  treated  on  post  stroke  day  
(PSD)  3  and  allowed  to  recover  until  PSD  14.  For  multiple  injection  studies,  mice  
were  treated  on  PSD  3,  6,  and  9  and  again  allowed  to  recover  until  PSD  14.  
  
Behavioral  Assessments:  
11-­point  Behavioral  Neurological  Score:  Mice  underwent  behavioral  assessment  
to  assess   the   following  behavioral  metrics:   level  of   consciousness   (LOC),  gaze  
(G),   visual   field   (VF),   sensorimotor   response   (SR),   and   grip   strength   and  
endurance/   paralysis   paw   hang   (PPH).   LOC   was   determined   prior   to   any  
disturbance  of  the  animal’s  cage  and  was  assessed  on  a  0-­2  severity  scale  with  0  
being  alert  and  active  without  outside  stimulus,  1  being  responsive  to  stimulus,  and  
2   being   huddled,   unresponsive,   and   non-­grooming.      Gaze   was   assessed   by  
passing   a   visual   stimulus   in   front   of   each   eye   in   turn  WITHOUT  disturbing   the  
mouse’s   whiskers.   The   subject   was   given   a   0   score   if   they   looked   toward   the  
stimulus  and  a  1  if  they  failed  to  do  so.  VF  was  assessed  by  holding  the  mouse  by  
	  85	  
the  tail  near  a  platform  (on  its  right  or  left  side)  and  if  the  mouse  reached  for  the  
platform  it  received  a  score  of  0.  If  it  did  not  reach  within  5  seconds,  it  was  given  a  
score  of  1  for  each  side  it  failed  on.  SR  was  scored  by  pressing  each  paw  in  turn  
to  elicit  a  reaction.  A  reaction  was  defined  as:  vocalizing  pain,  retracting  the  paw,  
or  jumping  in  response  to  the  paw  press.  A  lack  of  any  of  these  signs  resulted  in  a  
score  of  1  for  each  paw  affected.  Finally,  PPH  was  scored  by  a  typical  paw  hang  
test.  The  mouse  uses  its  front  paws  to  hang  from  a  rod  for  a  period  of  60  seconds.  
The  mouse   receives   a   score   of   0   if   it   is   able   to   hang   with   both   paws   without  
dropping  a  paw  below  the  level  of  the  rod  for  the  full  60  seconds.  A  score  of  1  is  
earned  if  the  mouse  drops  either  paw  without  falling.  The  time  of  the  first  “partial”  
paw  drop  is  also  recorded.  A  score  of  2  is  earned  if  the  mouse  falls,  releasing  both  
paws,  at  any  time  during  the  60  second  time  period.  The  total  scores  are  tallied  at  
the  conclusion  of   the   testing   to  assess  overall   function.  Other  summary  metrics  
such   as   “latency   to   first   paw   drop”   were   also   used   to   help   assess   fine   motor  
function.  
Open  Field  Behavioral  Assessment:  Each  subject  was  placed  in  its  own  2x2  box  
and   tracked   using   the   EthoVision   12   software   for   5   minutes.   Animals   were  
assessed  on  the  day  prior  to  stroke  surgery,  and  then  again  on  PSD  1,  3,  and  7.    
Parameters  tracked  include  total  distance  traveled,  average  velocity,  turn  angle,  
and  time  spent  in  center  zone.  The  center  zone  was  defined  as  being  all  area  within  
the  box  that  was  at  lease  5  inches  away  from  the  walls  of  the  box.  This  parameter  
allowed  us  to  track  anxiety  as  a  function  of  how  long  the  animal  ventured  into  the  




Gross   cellular   morphology   was   assessed   using   Hematoxylin   Eosin   staining.  
Mounted  sections  were   fixed  with  10%  phosphate  buffered   formalin.  They  were  
then  stained  using  standard  H&E  methods  with  Gill’s  Hematoxylin,  mounted  using  
DPX   Mountant   medium,   and   were   scanned   using   a   HP   Scanjet   G4050.   The  
scanned   images   were   input   into   NIH   Image   J   for   infarct   analysis   (123).   H&E  
dismorphic   areas   were   defined   as   regions   with   loss,   lower   density,   smaller,  
irregular  shaped  nuclei  or  irregular  tissue  patterning  from  surrounding  areas.  Areas  
were   calculated   using   the   ImageJ   free-­hand   selection   tool   and   summated   to  
calculate  final  dysmorphic  volume.  
  
Immunohistochemistry:    
Mounted,  20  um  tissue  sections  were  fixed  with  ice  cold  1:1  acetone:methanol  prior  
to  incubating  in  blocking  buffer  (5%  BSA  in  PBS  with  0.1%  Triton  X-­100)  for  one  
hour  at  room  temperature.    The  sections  were  then  incubated  overnight  at  4°C  in  
primary  antibody  (in  2%  BSA/0.1%  Triton  X-­100)  against  PECAM  (1:100)  Sections  
were   washed   and   incubated   with   a   fluorescent   secondary   antibody   (1:1000;;  
AlexaFluor   488   or   568,   Life   Technologies)   for   one   hour   at   room   temperature.    
Sections   were   washed   again   and   then   coverslipped   with   fluorescent  mounting  
media  containing  DAPI  (H-­1200,  Vector  Labs)  and  images  were  captured  using  a  
Nikon   Eclipse   Ti   microscope   and   software   (Nikon).   Images   were   analyzed   for  
antibody-­specific   positive   staining   using   ImageJ   (threshold   pixel   intensity  made  
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similar  across  all   images  to   isolate  antibody-­specific  staining  and  then  recorded  
the  number  of  stain  positive  pixels).    Results  are  from  3  sections  per  animal  and  
the  area  selected  was  in  the  infarct  core  identified  morphologically.  
  
Cell  Culture:  
Brain  microvascular  endothelial  cells   (BECs)   from  C57BL/6  mice  maintained  as  
cells   lines   (124,  130)  were  used   in   this  study.  C57BL/6  BECs  were  cultured  on  
porcine   gelatin-­coated   tissue   culture   plates   in   Iscove’s   Modified   Dulbecco’s  
Medium  (IMDM)  containing  10%  fetal  bovine  serum  (FBS),  1  U/mL  penicillin,  100  
mg/mL  streptomycin  and  1%  L-­glutamine,  and  were  kept  at  37°C  and  5%  CO2.  
Cells  were  grown  to  confluence  and  were  treated  with  IL-­1a as  indicated.  RNA  
was  collected  2,  4,  or  6  hours  after  treatment  and  purified  using  pureLink  RNA  kit  
(Invitrogen).  RNA  was  then  reverse  transcribed  and  levels  of  IL-­1a  cathepsin  B,  
cathepsin   L,   and   perlecan   were   determined   using   Viia7   software   and   TaqMan  
probes  and  reagents.  
  
Statistical   Analysis:   All   experiments   were   performed   on   at   least   replicated  
studies,  and  each  treatment  group  contained  at  least  4  mice.  Data  are  represented  
as  mean  ±  SE  of   the  mean  (SEM).  Comparison  between  two  groups  was  done  
using   the   Student’s   t-­test.   Comparison   between   three   or   more   groups   was  
performed  using  one-­way  ANOVA  followed  by  a  Tukey’s  post  hoc  analysis.  We  
analyzed  time  course  behavioral  data  (such  as  open  field  and  11-­point  neuroscore)  
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by  two-­way  ANOVA  and  Bonferroni  post  hoc  test.  Significance  was  determined  by  
a  p  value  of  <  0.05.  
  
Results:  
IL-­1a  is  differentially  upregulated  in  different  cell  types  in  various  phases  of  stroke.  
IL-­1a   is   expressed   by  many   types   of   cells   and   this   expression   is   known   to   be  
dependent   on   both   disease   state   and   time   (83).   Particularly,   microglia   (145),  
platelets  (146),  and  leukocytes  (105,  128)  are  known  sources  of  IL-­1a  in  various  
disease  states.  We  were,  therefore,  interested  to  determine  by  which  types  of  cells  
IL-­1a  was  expressed  following  stroke.  According  to  (83),  the  initial  upregulation  of  
IL-­1a   following   ischemia  occurs   in  as   little  as  4  hours,  while,  more   recently  Dr.  
Buckwalter’s   group   at   Stanford   has   shown   that   IL-­1a   is   upregulated   nearly   2  
months  post  stroke  (118,  147).  Our  group  was  interested  in  seeing  whether  this  
persistent   upregulation   of   IL-­1a   was   through   a   single   cell   type   or,   as   we  
hypothesized,   its   prolonged   presence   in   the   brain  was   due   to   several   different  
types  of  parenchymal  and  peripheral  cells.    Due  to  the  nature  of  IL-­1a  being  an  
established   pro-­inflammatory   cytokine,   we   decided   to   look   at   IL-­1a   expression  
changes   in   astrocytes   and   in   microglia.   Additionally,   because   of   previously  
published  work  at  the  University  of  Manchester,  we  also  chose  to  look  at  changes  
in  IL-­1a  expression  within  platelets  (146).  Interestingly,  we  found  that,  at  24  hours  
post  stroke,  microglial  IL-­1a  (Figure  4.1A)  accounted  for  nearly  80%  of  all  IL-­1a  
expression;;  while,  at  14  days  after  stroke,  it  only  accounted  for  20%  of  all  IL-­1a  
expression  within   the  periinfarct   region   (Fig.  4.1D).   Inversely,  at  24  hours  after  
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stroke,  platelets  accounted  for  none  of  the  periinfarct  IL-­1a  expression;;  while,  after  
2  weeks,  platelets  account   for  over  80%  of   the   total   IL-­1a      expression   (Figure  
4.1B).  Surprisingly,  astrocytes  accounted   for  none  of   the   total   IL-­1a  expression  
(Figure  4.1C)  within   the  periinfarct   region  at  either  examined   time  point.  Taken  
together,   these   data   suggest   that   after   the   acute   phases   of   stroke,   the   brain  
receives  IL-­1a  from  peripheral  sources,  thus  making  our  treatment  of  stroke  with  
IL-­1a,  less  likely  to  significantly  impact  peripheral  systems.  
  
IL-­1a  treated  animals  have  less  (subacute)  tissue  damage  than  vehicle.  
Next,  we  aimed  to  discern  IL-­1a’s  ability  to  affect  overall  tissue  morphology  when  
given  following  stroke.  In  this  experiment,  we  treated  stroked  animals  via  tail  vein  
injection  at  post  stroke  day  (PSD  3)  in  an  effort  to  avoid  affecting  neuroprotective  
pathways.  As  our  model  typically  reaches  its  maximum  volume  at  day  3,  we  chose  
that  day  to  treat  our  mice  (123).  Upon  sacrifice,  brains  were  analyzed  for  overall  
tissue  morphology  using  H&E  staining  as  described  above.  We  found  that  animals  
treated  with   IL-­1a   had   less  overall   tissue  dysmorphia   than   their   vehicle   control  
counterparts  (Figure  4.2A  and  B)  (dysmorphic  volume-­  vehicle:  17.64  ±  3.84  mm3  
vs  IL-­1a:  6.83  ±  2.24  mm3).  Data  are  represented  as  mean  ±  SEM.  n  =  6  per  group.    
IL-­1a  treated  animals  have  more  activated  endothelial  cells  in  the  periinfarct  region  
Next,  we   looked   to   see  whether   our   overall   histological   findings  as  well   as   the  
observed  functional  benefit  could  be  due  to  a  “jump  started”  angiogenic  response.  
Tissue  sections  were  therefore  stained  for  ICAM-­1,  a  known  marker  for  endothelial  
cell   activation.  We   found   that  animals   treated  with   IL-­1a   had  significantly  more  
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ICAM-­1  positive  staining  than  did  animals  receiving  vehicle  treatment  (Figure  4.3)  
(Student’s  t-­test  **p<0.01  vehicle:  4317  ±  1247  positive  pixels  vs  IL-­1a:  15000  ±  
2551  positive  pixels).  We  observed  that  while  all  histological  data  came  from  the  
periinfarct   areas,   ICAM-­1   expression  was   only   particularly   strong   in   the   striatal  
periinfarct.  Data  represent  mean  ±  SEM.  n=5  per  group.  
  
IL-­1a  treated  animals  have  more  vascular  density  in  the  periinfarct  region  
Because  of  the  observed  striatal  endothelial  cell  activation,  we  next  looked  to  see  
whether  there  was  any  evidence  that  cortical  angiogenesis  had  already  concluded.  
To  do  this,  we  stained  for  overall  vascular  density  using  PECAM-­1  (CD31).  We  
found   that   IL-­1a   treated   animals   had   increased   overall   vascular   density   in   all  
periinfarct  regions  (including  in  the  striatum)  (Figure  4.3  and  4.4)  (Student’s  t-­test  
*p<0.05  vehicle:  615106  ±  62943  positive  pixels  vs  IL-­1a:  761564  ±  18901  positive  
pixels).  This  suggested   to  us   that  we  had  either  missed   the  window   for  cortical  
angiogenesis  and  we  were  catching  the  end  of  striatal  angiogenesis  or  that  IL-­1a  
was  particularly  effective  at  inducing  angiogenesis  in  the  striatum.      
  
IL-­1a   treated   animals   show   greater   expression   of   doublecortin   at   the  
subventricular  zone  
We  next  aimed  to  show  whether  IL-­1a  could  enhance  other  reparative  processes  
in  addition  to  angiogenesis.  To  investigate  this,  we  labelled  brains  from  the  above  
experiments   (sacrificed   at   PSD   14)   for   the   presence   of   doublecortin   (DCX),   a  
marker   of   immature   neuroblasts.   We   found   that   animals   receiving   IL-­1a   had  
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significantly  more  DCX  positive  staining  at  the  SVZ  (Figure  4.5)  (Student’s  t-­test  
*p<0.05   vehicle:   9470  ±   2742  positive   pixels   vs   IL-­1a:   36644  ±   11553  positive  
pixels).,   suggesting   that   IL-­1a   could   be   enhancing   neurogenesis.   Data   are  
represented  as  mean  ±  SEM.  n  =  6  per  group  
  
IL-­1a  treated  animals  exhibit  accelerated  functional  recovery  after  delayed  IL-­1a  
treatment  
We  next  wanted  to  determine  whether  IL-­1a  treatment  enhances  functional  benefit  
when  given  3  days  following  stroke.  The  animals  described  above  were  subjected  
to  a  battery  of  neurological  tests  summated  into  an  11-­point  neurological  severity  
score  (NSS).  Both  groups  showed  similar  functional  deficit  in  their  total  NSS  on  the  
day   following  stroke  surgery  as  expected  (vehicle:  6.75  ±  1.03  vs   IL-­1a:  6.40  ±  
0.812).   1  day  after   treatment,   at  PSD4,   the  animals   treated  with   IL-­1a   showed  
significant  functional  recovery  compared  to  vehicle  controls  (vehicle:  6.50  ±  1.04  
vs   IL-­1a:   4.00  ±   0.447).  This  effect   seemed   to  diminish  as   the  mice   recovered  
suggesting  the  potential  need  for  a  multi  dose  treatment  regimen  instead  (Figure  
4.6).  
Repeated  dosing  of  IL-­1a  does  not  improve  outcomes  
From  our  data  in  Figure  4.6,  we  concluded  that  one  single  bolus  dose  of  IL-­1a  at  
PSD  3  was  likely  not  sufficient  to  sustain  the  functional  improvement  seen  at  PSD  
4  (one  day  following  IL-­1a  treatment).  We  therefore  examined  whether  a  repeated  
dosing  regimen  would  show  additive  benefit.  In  this  experiment,  we  induced  stroke  
and  then  treated  the  animals  with  either  PBS  or  IL-­1a  starting  on  PSD  3  and  then  
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again   on   days   PSD   6   and   PSD   9.   In   addition   to   there   being   no   significant  
histological  improvement  (Student’s  t-­test  p  =  0.72),  the  IL-­1a  treated  mice  appear  
to   have   similar   or   worse   behavioural   outcomes   compared   to   vehicle   controls  
(Figure  4.7)  (2way  ANOVA  p  =  0.8629).  n  =  10  per  group      
  
IL-­1a  treatment  increases  mRNA  expression  of  perlecan  and  cathepsin  B  in  vitro  
Finally,  we  wanted  to  see  whether  IL-­1a  imparts  its  angiogenic  effects  through  LG3  
as  was  evidenced  in  Chapter  2.  To  do  this,  we  treated  BECs  with  IL-­1a  as  detailed  
in  Chapter   3.  We   then   collected   RNA   from   wells   2,   4,   and   6   hours   following  
treatment   to  see  how  the  expression  of   IL-­1a,  cathepsin  B  and  L,  and  perlecan  
changed  over  time.  We  found  that  the  most  noticeable  changes  in  each  of  these  
genes   occurred   4   hours   post-­treatment   and,   at   that   time,   showed   significant  
increases  in  cathepsin  B  (Figure  4.8A)  (One-­Way  ANOVA  *p<0.05  vehicle:  1.01  
±  0.093   fold  vs   IL-­1a:  2.24  ±  0.45   fold   increase)  and   in  perlecan  (Figure  4.8B)  
(One-­Way  ANOVA  *p<0.05  vehicle:  1.03  ±  0.16  fold  vs  IL-­1a:  1.909  ±  0.38  fold  
increase).  We  also   found   that   the   increase   in  cathepsin  B   is  partially  abolished  
when  we  inhibit  IL-­1R1  with  IL-­1RA  (IL-­1a  +  IL-­1RA:  1.31  ±  0.11  fold)  but  that  the  
increase  in  perlecan  is  not  affected  (IL-­1a  +  IL-­1RA:  1.77  ±  0.063  fold)  suggesting  
that   IL-­1a’s  effect  on  perlecan  is  receptor   independent.  Because  LG3  has  been  
shown  to  be  released  predominantly  through  cathepsin  B  proteolysis  (99,  100),  we  




Figure  4.1  IL-­1a  expression  varies  based  on  cell  type  and  phase  of  stroke.  Brains  
from  stroked  mice  stained  for  IL-­1a   in  various  cell   types:  microglia  (A),  platelets  
(B)  and  astrocytes  (C)  up  to  2  weeks  after  stroke.  IL-­1a  is  predominently  expressed  
in  microglia  (1  day)  (A,  D)  and  platelets  (14  days)  (B,  E)  after  stroke.  IL-­1a  was  not  




























































Figure  4.2  Delayed  IL-­1a  treatment  results  in  less  cellular  dysmorphia  at  PSD  14.  
(A)  Scans  of  whole  mouse  brain  tissue  sections  stained  for  H&E.  (B)  Quantification  































Figure  4.3  Delayed  IL-­1a  increases  expression  of  markers  of  vascular  activation  
PECAM  and  ICAM  expression  in  the  periinfarct  region.  Representative  images  of  
stains  for  (A)  PECAM  and  (B)  ICAM-­1.  Quantification  of  (C)  PECAM  and  (D)  ICAM-­
1.   These   stains   show   more   vascularization   and   more   EC   activation   14   days  




























































Figure  4.4  Delayed  IL-­1a  increases  VEGFR2  expression  in  the  periinfarct  region.  

















































Figure  4.5  Delayed  IL-­1a  increases  DCX  expression  at  the  SVZ.  Representative  
images   of   brains   from   stroked   mice   stained   (A)   for   doublecortin   (DCX)   at   the  
subventricular  zone  (SVZ)  14  days  following  stroke.  Quantification  of  DCX  stains  
(B)  show  more  DCX  positive  staining  at  the  SVZ  with  IL-­1a  treatment  compared  to  
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Figure  4.6  Delayed  IL-­1a  imparts  fleeting  functional  benefit  which  diminishes  over  
time   Graphs   showing   increased   functional   recovery   with   IL-­1a   (Treatment   2)  
compared  to  PBS  Vehicle  (Treatment  1)  as  early  as  4  days  following  stroke  on  an  
11  point  (A)  and  on  a  28  point  (B)  neurological  score.  Both  tests  show  that   this  
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Figure   4.7   Giving   multiple   injections   of   IL-­1a   is   not   beneficial   and   could   be  
detrimental  to  post-­stroke  recovery.  Graphs  showing  (A)  weight  gain  over  PSDs  1-­
14,   (B)   infarct  volume  measured  by  H&E  stain,   (C)   total  neurological  score,   (D)  
total  paw  hang  time,  and  (E)  latency  to  first  foot  fault  on  the  paralysis  paw  hang  
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Figure   4.8   IL-­1a   treatment   increases   mRNA   expression   of   cathepsin   B   and  
perlecan   in   vitro.  Mouse  brain  endothelial   cells   treated  with  1ng/mL   IL-­1a   for  4  
hours   express   more   cathepsin   B   (A)   and   perlecan   (B)   mRNA.   This   effect   is  






















In  this  study,  we  aimed  to  investigate  the  potentially  reparative  effects  of  IL-­1a  in  
the  context  of  stroke  in  vivo.  Our  previous  research  described  that  IL-­1a’s  overall  
expression  in  the  brain  remained  elevated  up  to  a  week  after  stroke  (98).  In  order  
to  more  clearly  determine  IL-­1a’s  pattern  of  expression,  we  tested  cells   that  we  
and  others  (83)  know  to  be  IL-­1a  contributors  in  various  disease  states.    We  were  
unsurprised  to  find  that  microglia  were  the  principal  cellular  source  of  IL-­1a  acutely  
and  that  platelets  are  the  principle  source  of  IL-­1a  in  more  chronic  phases  of  stroke  
injury.   Additionally,   we   confirmed   what   others   (99,   148)   had   previously  
demonstrated.  We  found  that  astrocytes  did  not  contribute  to  IL-­1a  production  at  
either  1  day  and  14  days  after  stroke.  It  is  possible,  but  not  likely,  that  astrocytic  
contribution  of  IL-­1a  expression  occurs  at  an  interim  time  point  which  we  did  not  
investigate  (99,  148).  However,  other  labs  have  more  recently  discovered  that  IL-­
1a   is  elevated  even  out   to  7  weeks  following   ischemic   injury  (118).  This   finding  
suggests   that   IL-­1a   could   have   additional   significant   roles   in   more   long-­term  
phases   of   injury   progression   and   repair   which   highlights   new   questions   to   be  
studied   and   answered.   Specifically,   it   has   not   been   determined   whether   IL-­1a  
overexpression  diminishes  after  7  weeks.  It  is  not  yet  known  exactly  how  long  IL-­
1a  remains  elevated  in  the  chronic  post  stroke  brain  and  even  less  is  understood  
of  its  function  in  the  brain  recovery  process  that  far  removed  from  the  initial  injury.      
  
We  also  saw  that  IL-­1a   treated  mice  showed  less  overall  damage,  more  overall  
vascularization  and  BEC  activation  within  the  periinfarct  area,  and  showed  modest  
	  103	  
improvement  on  functional  tests.  The  lack  of  significant  functional  benefit  could  be  
due  to  the  single  dose  of  IL-­1a  being  insufficient  for  long  lasting  effect.  However,  
we   next   discovered   that   too   much   or   too   frequent   IL-­1a   treatment   can   be  
detrimental   for   both   histological   and   functional   recovery.   Finally,   we   wished   to  
determine  IL-­1a’s  downstream  mediators  and  we  found  that  IL-­1a  is  likely  acting  
through  cathepsin  B  and  perlecan  upregulation  to  produce  LG3  which  we  know  to  
be  neuroprotective  and  proangiogenic  (99,  100).    
  
As  seen  in  Chapter  2,  again  in  Chapter  3,  and  finally  within  this  chapter,  IL-­1a  is  
damaging  and  even  toxic  when  given   in  too  high  a  concentration  OR  when  it   is  
given  too  frequently.  We  hypothesized  that  giving  IL-­1a  in  bolus  doses  every  72  
hours  would  provide  sufficient  time  for  IL-­1a  to  adequately  clear.  We  based  this  on  
the   fact   that   the   half-­life   for   IL-­1a,   unlike   IL-­1b,   is   15   hours   (149)   and,   since  
clinicians  typically  wait  4  or  5  half-­lives  to  administer  additional  dosing  (150),  we  
concluded  that  this  was  a  clinically  relevant  and  safe  regimen  with  which  to  start.  
As  was  shown  in  Figure  4.7,  this  assumption  proved  to  be  incorrect  in  our  hands.    
  
This  failure  has  at  least  two  reasonable  explanations.  The  first,  and  most  likely,  is  
that   the   constant,   low-­grade   inflammation   over   the   span   of   nearly   two   weeks  
caused  significant  detriment,  not  only  in  the  brain,  but  also  in  peripheral  organs.  
This  could  be  addressed  by  comparing  splenic  volume  of  treated  mice  to  those  of  
vehicle  (PBS-­injected)  animals  (151)  at  each  time  point  following  stroke  and  also  
after   each   subsequent   injection   of   IL-­1a.   As   Dr.   Pennypacker   and   his   lab  
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discovered,  the  spleen  contracts  and  releases  its  contents  in  a  peripheral  response  
to  ischemic  stroke  (151,  152).  One  could  hypothesize  that  this  could  be  happening  
with   each   additional   injection   of   IL-­1a,   thus   propagating   the   damaging  
inflammatory  cell  and  cytokine  release  each  time.  (151,  153).          
  
The  failure  of  IL-­1a  to  produce  additive  benefit  with  each  injection  emphasizes  the  
need   to   pursue   less   pleiotropic,   more   targeted   therapeutics.   In   the   in   vitro  
experiments   discussed   here,   along  with   our   previous   published  work,  we   have  
demonstrated  that  a  key  downstream  effector  of  IL-­1a  is  the  C-­terminal  fragment  
of  perlecan,  LG3  (99,  100).  In  other  work,  we  have  shown  that  perlecan  DV  and  
LG3  are  proangiogenic  following  stroke  and  that  both  peptides  traffic  to  the  site  of  
injury  (123,  124).  These  discoveries  point  to  LG3  as  a  candidate  for  future  studies  
as  a  less  damaging  and  more  targeted  endogenous  therapy  for  use  in  both  acute  
and  chronic  phases  of  stroke.  
  
Conclusion  
Taken  together  our  results  show  that   IL-­1a  significantly  enhances  angiogenesis  
and  could  enhance  early  neurogenesis  when  given   three  days   following  stroke.  
We  have  also  established  the  safe  and  effective  limit  on  how  much  and  how  often  
IL-­1a  can  be  administered  before  seeing  adverse  effects.  Finally,  we  have  shown  
a   potential  mechanism   of   action   for   IL-­1a   and,   in   so   doing,   have   identified   an  
attractive  target  for  future  drug  discovery  studies.  
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Chapter  5:  Discussion  
This  discussion  will  be  divided  into  four  sections.  It  will  begin  with  a  brief  summary  
of   chapters   2   through   4.   Next   it   will   discuss   technical   challenges   and   caveats  
experienced  during  each  study.  Then,  it  will  discuss  IL-­1a’s  likely  mechanisms  of  
action  and  how  it  fits  in  with  the  current  literature.  It  will  conclude  by  discussing  the  
clinical  implications  of  the  work  presented  above  as  well  as  the  future  directions  of  
this  project  in  the  lab.  
Summary  
While  more  and  more  patients  are  surviving  stroke,  stroke  remains  a  leading  cause  
of   long-­term   disability   worldwide   (154).   Despite   promising   preclinical   data  
investigating   the   potential   benefits   of   anti-­inflammatory   based   therapy,   clinical  
trials  studying  them  in  patients  have  all  failed  to  yield  promising  results  (113).  We  
hypothesized   that   this   failure   to   produce   effective   therapies   aimed   at   blocking  
inflammation  after  stroke  is  due  to  the  fact  that  both  good  and  bad  inflammation  is  
being  targeted.  We  therefore  focused  the  research  described  here  on  determining  
the  unique  role  of  IL-­1a  as  it  relates  to  protection  from  stroke  injury  and  to  post  
stroke  recovery.  
We  initially  began  by  determining  whether  a  low  dose  of  IL-­1a  would  be  safe  to  
administer  via  IV  injection  in  post  stroke  mice.  We  found  it  not  only  to  be  safe,  but  
also   protective   from   ischemic   injury   on   histological   stains.   In   order   to   further  
demonstrate   its   safety,  we  measured   key   vital   statistics   over   approximately   30  
minutes   following   reperfusion   and   injection   and   found   that   IL-­1a   induced  
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significant,  albeit  transient,  changes  in  heart  rate  and  pulse  distension.    
To  address  this  concern,  we  turned  to  an  alternative  injection  method  which  we  
had   previously   established   to   be   safe   and   effective   at   delivering   a   very   small  
volume  of  drug  to  the  desired  area  of  the  brain  (120).  This  method  was  chosen  to  
minimize  the  systemic  effects  seen  with  the  IV  injection  paradigm.  Although  this  
injection  method  added  an  additional  surgical  variable,  we  did  not  see  significant  
differences  between   IV  and   IA   treated  animals   regarding  behaviour  or   recovery  
time.  Additionally,  this  injection  method  is  highly  clinically  relevant  due  to  the  usage  
of  endovascular  thrombectomy  in  cases  of  large  vessel  occlusion.  The  proximity  
of  the  shuttle  to  the  area  of  occlusion  in  surgical  thrombectomy  is  similar  to  where  
we  place  the  tubing  in  our  model  of  IA  drug  delivery.    
Our  hypothesis  that  giving  less  IL-­1a   in  closer  proximity  to  the  area  of   ischemia  
would  result  in  fewer  side  effects  was  correct.  We  found  that  treating  the  animals  
with   IA   IL-­1a   reduced   the   histological   damage   still   further   while   abolishing   the  
negative  side  effects  of  IV  IL-­1a  administration.  Additionally,  we  found  that,  even  
with   the  more   invasive  surgery,   the   IA  and   IV   IL-­1a   treated  animals  performed  
similarly  well  compared  to  each  other  and  significantly  better  than  their  respective  
controls.    
We  then  wished  to  test  whether  IL-­1a  could  induce  reparative  processes  such  as  
angiogenesis  and  neurogenesis  in  the  subacute  and  chronic  phases  of  stroke.  In  
this  case,  we  could  not  administer  IA  IL-­1a   in  a  way  that  was  clinically  relevant.  
We  therefore  administered  IV  IL-­1a  with  the  knowledge  that  the  side  effects,  while  
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undesirable,   were   non-­lethal   and   transient.   We   saw   that   the   mice   performed  
moderately   better   on   a   behavioural   battery   of   tests   on   the   day   following   IL-­1a  
treatment  (PSD  4),  had  more  overall  brain  vasculature,  and  had  more  endothelial  
activation  out   to   two  weeks  after  stroke.  We  also  saw  that  mice  receiving  IL-­1a  
showed  significantly  more  immature  neuroblasts  at  the  SVZ  suggesting  that  IL-­1a  
could  affect  early  post-­stroke  neurogenesis.  Because  the  animals  did  not  exhibit  
the  expected  long-­term  behavioural  benefits,  we  attempted  a  multi-­dose  IV  IL-­1a  
regimen  which  ultimately  failed.  In  fact,  the  treatment  of  IL-­1a  on  every  third  day  
following   stroke,   starting   on   PSD   3,   resulted   in   worse   performance   on   our  
behavioural   battery  of   tests  and  showed  worse  histological  damage   than   those  
mice  which  had  received  only  one  dose  of  IL-­1a.    
We  next  wished  to  elucidate  the  mechanism  behind  IL-­1a’s  multifaceted  effects.  
We  first  examined  the  mechanism  behind  IL-­1a’s  reparative  activity   in  vitro.  We  
wanted   to   1)   confirm   that   IL-­1a   was   acting   on   IL-­1R1   as   had   been   previously  
published  (88)  and  2)  whether  IL-­1a  was  acting  through  its  interaction  with  ECM  
protein  perlecan  to  impart  its  pro-­angiogenic  effects.  Through  our  experiments  with  
IL-­1RA  outlined   in  Chapter  3,  we  found  that   IL-­1a  was   indeed  acting  on  IL-­1R1  
and  additional  experiments  (found  in  Chapter  4)  showed  that  IL-­1a  was  inducing  
the  expression  of  both  perlecan  and  cathepsin  B,  a  protease  previously  shown  to  
proteolyze  perlecan  and  release  LG3.    
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We  next  investigated  how  IL-­1a  was  imparting  its  neuroprotective  effect  in  vivo.  To  
test   this,  we  administered   IL-­1a   to  mice  which   lacked  perlecan’s  LG3   fragment  
and,  in  agreement  with  our  hypothesis,  we  saw  that  pln  KO  mice  did  not  achieve  
neuroprotection  with  IL-­1a  treatment.  Having  both  in  vitro  and  in  vivo  mechanistic  
data  showing   that   IL-­1a  was   likely   to  act   through   IL-­1R1  and  LG3   to   impart   its  
angiogenic   and   neuroprotective   activity,   we   hypothesized   that   IL-­1a   would   be  
unable  to  impart  direct  neuroprotection  in  the  absence  of  IL-­1R1.  To  test  this,  we  
treated   primary   cortical   neurons   exposed   to   30   minutes   of   OGD   or   NMDA  
incubation   (to   model   excitotoxicity)   with   several   concentrations   of   IL-­1a.   As  
expected,  we  found  that  excessive  IL-­1a  is  toxic  to  neurons  with  or  without  OGD  
exposure.  However,  we  also  saw  that  lower  doses  of  IL-­1a   imparted  significant,  
direct  protection  in  absence  of  any  other  cell   type.  We  concluded  that  our   initial  
hypothesis  that  IL-­1a  was  acting  exclusively  through  IL-­1R1  was  wrong  and  that  it  
was  likely  also  acting  through  neuronal  IL-­1R3.  This  observation  showed  us  that  
IL-­1a  could  be  acting  in  a  much  more  pleiotropic  way  and  has  forced  us  to  focus  
more  on  this  neuroprotective  and  reparative  mechanism  from  the  perspective  of  
proteins  more  downstream  in  IL-­1a’s  signalling  cascade.  
One   finding,   shown   in   Figure   2.3,   demonstrated   that   administering   IL-­1a  
dampened   the   CD11b   positive   signal   (IV<IA).   As   we   were   injecting   a  
proinflammatory   cytokine   into   an   already   inflamed   system   following   stroke,   we  
anticipated  to  see  little  to  no  change  in  microglial  activation.  Seeing  this  reduction  
in  CD11b  signal  in  the  IV  treated  animals  and  even  more  of  a  reduction  in  the  IA  
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treated  animals  led  us  to  hypothesize  one  of  two  possible  reasons.  The  first  being  
that   the   reduction   in  CD11b  positive  staining  was  secondary   to   reduced  overall  
injury.  We  believe  that  this   is  the  more  likely  scenario.  The  second  possibility   is  
that   IL-­1a   is  affecting  microglial  phenotype.  This  conclusion  was,   initially,  highly  
unlikely  due  to  IL-­1a  being  an  established,  proinflammatory  cytokine.  However,  a  
collaborator  at  the  University  of  Manchester  has  recently  shown  that  priming  BV2  
microglial  cells  with  IL-­1a  can  induce  an  anti-­inflammatory  phenotype  in  vitro  (155).  
This  presents  a  new  possibility  for  IL-­1a’s  mechanism  of  action  which  is  discussed  
later   in   this   chapter.   Put   together,   our   findings   present   several   new   and  
complicated  questions  that  must  be  answered  for  effective  IL-­1a  translation.  
Technical  Challenges  
In  all  of  our  surgical  experiments,  we  used  a  transient,  distal  MCA  occlusion  model  
of  stroke.   In   this  model,  each  mouse  was  subjected   to  either   tandem   ipsilateral  
CCA  and  MCA  occlusion  for  1  hour  or  sham  surgery  as  previously  published  (123).  
In  our   lab,   this  procedure  has  a  very   low  mortality   rate   (<5%)   (123).  The  sham  
surgical   control   animals   received   the   same   amount   of   anesthesia,   the   same  
incisions,  and  the  same  vessel  manipulation  as  those  mice  which  received  the  full  
stroke  surgery.  The  only  differences  were  the  placement  (or  non-­placement)  of  the  
micro  clamp  on  the  CCA  and  the  filament  under  the  MCA  distally.    
While   this  model   induces   a   clinically   relevant   infarct,   there   are   features   of   the  
model,   independent  of   treatment  group,  which  could  affect   the  variability  of   the  
infarct.  These  are  important  to  note  because  they  could  inadvertently  be  increasing  
the   risk   of   statistical   error.   The   first   potential   source   of   variability   is   the   brain  
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vasculature   of   the   mice.   Even   though   we   are   working   with   genetically  
similar/identical  mice,  brain  vasculature  often  has  small  variances  which  can  cause  
a   mouse   to   have   a   larger   or   smaller   stroke   than   normal.   This   can   introduce  
randomness  and  can  put  us  in  danger  of  both  type  I  and  type  II  statistical  errors.  
By  performing   these  experiments   in  a   randomized,  blinded   fashion  we  hope   to  
avoid  these  errors;;  however,  it  is  important  to  note  that  these  potential  sources  of  
variability  exist  in  our  model.    
To  determine  whether  perlecan  LG3  is  necessary  for  IL-­1a  to  impart  its  therapeutic  
effects,  we  chose  to  use  perlecan  hypomorph  (abbreviated  in  Figure  2.7  as  Pln  
KO)  mice.  Perlecan  hypomorph  mice  were  developed  by  the  Jacenko  lab  at  the  
University  of  Pennsylvania  School  of  Veterinary  Medicine  in  an  effort  to  model  a  
form   of   chondrodysplasia   called   Schwartz-­Jampel   syndrome   (156).   In   the  
development  of  the  mouse  line,  the  cassette  which  the  authors  inserted  resulted  
in   defective   transcription   of   perlecan.   The   mice   express   a   truncated   form   of  
perlecan   (lacking   Domain   V)   and,   additionally,   this   perlecan   is   not   effectively  
secreted  (10%  of  normal  secretion)  (156).  Despite  the  lack  of  perlecan,  these  mice  
do   not   carry   an   altered   cerebrovascular   phenotype   (123,   124).   This   strain  was  
chosen  instead  of  one  which  completely  lacks  perlecan  for  three  reasons:  firstly,  
and  most  compellingly,  complete  deletion  of  perlecan  results  in  embryonic  lethality.  
Secondly,  our  hypothesis  is  based  on  deletion  of  only  the  fifth  domain  of  perlecan,  
specifically  of  LG3  which  is  the  most  C-­terminal  fragment  of  perlecan  and  is  the  
easiest   to   selectively   delete.   Finally,   caution  must   be   used   in   interpreting   data  
obtained  with  genetic  manipulation,  especially  with  genetic  deletion.  While  it  is  a  
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useful   tool,   mammalian   biology   is   highly   adaptable   and,   as   such,   is   likely   to  
compensate  for  the  absence  of  such  an  important  protein.  Fortunately,  our  lab  will  
soon  be   receiving  perlecan   floxed  mice   from  Dr.  Thompson   from   the  School  of  
Health  and  Rehabilitation  Sciences  at  Indiana  University  in  Indianapolis,  IN.  This  
particular  line  of  mice  will  allow  our  lab  to  perform  cell-­specific  perlecan  deletion  
which  will  allow  us  to  determine  the  most  important  cellular  sources  of  perlecan  in  
the  context  of  stroke  and  post-­stroke  treatment.    
Another   technical   challenge  which  we   faced  was   encountered   during   the  work  
presented   in   Chapter   4.   In   performing   the   experiments   with   repeated   IL-­1a    
administration,  we  had  originally  intended  on  administering  an  additional  injection  
on  PSD  12.  However,  each  subsequent  injection  became  more  and  more  difficult  
due   to   the   tail  vein  becoming  damaged  and,   in  some  cases,  necrotic.  This  was  
largely  expected  as  we  were   injecting  a  potent  pro-­inflammatory  cytokine   into  a  
very  small  vein  though  it  became  problematic  as  it  reduced  the  number  of  animals  
receiving  the  full  dosage.  As  all  of  these  studies  were  conducted  and  analyzed  in  
an   “as-­treated”   fashion,   the   number   of   failed   injections   due   to   injection   site  
inflammation  and  necrosis  greatly  reduced  the  power  of  our  experiment.  By  the  
third  injection  (PSD  9),  it  became  apparent  that  adding  a  fourth  injection  was  not  
feasible  and  so  the  study  was  adjusted  to  only  include  three  injections.  
  
Understanding  IL-­1a’s  mechanism:  
As  summarized  in  Figure  5.1,  our  data  shows  that  IL-­1a  works  through  its  receptor  
(IL-­1R1)  to  elicit  its  repair  response  in  vitro.  Presumably,  this  means  that  IL-­1a’s  
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activity   depends   on   factors   downstream   to   impart   its   protective   and   reparative  
effects.  To  further  support  this  idea,  IL-­1R1  behaves  very  much  like  a  transporter  
rather  than  a  typical  cell  surface  receptor  in  the  brain,  suggesting  that  IL-­1a  could  
be  actively  transported  across  the  blood-­brain  barrier  rather  than  having  to  depend  
on   an   open   barrier   to   access   its   target(s).   Additionally,   our   findings   that   IL-­1a  
treatment  causes  the  upregulation  of  perlecan  and  cathepsin  B  (Figure  4.8A  and  
B)  shows  that  IL-­1a  could  be  acting  on  the  barrier  itself  to  either  enhance  repair  or  
to   release   protective   elements   of   the   barrier   during   inflammatory   phases   of  
ischemia.  This  possibility  is  supported  by  our  previous  work  demonstrating  that  IL-­
1a  stimulates  cultured  primary  mouse  brain  endothelial  cells  to  generate  LG3,  and  
that  administered  LG3  is  neuroprotective  after  OGD  in  vitro  (100).  
A  brief  review  of  the  current  literature  shows  that  the  IL-­1  signaling  cascade  has  
been  thoroughly  investigated  in  more  upstream  stages.  For  example,  others  have  
described   one   complete   pathway   in   which   IL-­1a-­IL-­1R1   binding   results   in   the  
recruitment   of   IL-­1   receptor   associated   kinases   (IRAKs)   and   the   subsequent  
activation   of   MAP3K7   (157).   MAP3K7   then   activates   well-­known   transcription  
factor,   NF-­kB   (157).  While   NF-­kB   is   understood   to   be   quite   a   broad-­spectrum  
transcription  factor,  we  have  found  literature  to  link  it  to  both  cathepsin  B  (158)  and  
to   perlecan   (159).   This,   combined   with   our   data   showing   that   IL-­1a   treatment  
increases  cathepsin  B  and  perlecan  mRNA  in  vitro  (Figure  4.8),  further  supports  
our   hypothesis   that   IL-­1a   works   through   controlled   proteolysis   of   perlecan   to  
release  its  C-­terminal  fragment,  LG3.  
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To  further  investigate  this  idea  that  IL-­1a  works  through  perlecan  LG3,  we  used  
pln  KO  mice  described  above  (123,  124,  156).  After  choosing  our  pln  KO  model,  
we  designed  our  experiment  to  mimic  our  previous  neuroprotection  experiments  in  
WT  mice  with   the   addition   of  WT   controls.  All  mice  were   treated  with   IV   IL-­1a  
immediately  upon  reperfusion  and  sacrificed  on  PSD  3.  Unsurprisingly,  we  found  
that   IL-­1a   treatment   did   not   provide   the   same  neuroprotection   in   pln  KO  mice.  
These  data  are  additionally  supported  by  our  previous  work  demonstrating  that  IL-­
1a  stimulates  cultured  primary  mouse  brain  endothelial  cells  to  generate  LG3,  and  
that  administered  LG3  is  neuroprotective  after  OGD  in  vitro  (100).  We  now  show  
that   IL-­1a   increases  mRNA   levels  of  perlecan  and   the  protease  cathepsin  B   in  
cultured  brain  endothelial  cells.  Cathepsin  B,  in  turn,  cleaves  perlecan  to  generate  
neuroprotective  LG3.  These  results  suggest  a  feed-­forward  mechanism  by  which  
IL-­1a   increases  both   the  production  of  perlecan  and   the  necessary  protease   to  
generate   LG3   from   perlecan   from   endothelial   cells,   leading   to   neuroprotection.  
(graphically  summarized  in  Figure  5.1A).      
The  above  mechanism  seems  to  make  sense  based  on  the  majority  of  our  findings,  
but   it   is   complicated  by   the   data   shown   in  Chapter   3   in  which   IL-­1a   is   directly  
protective  from  both  NMDA  induced  toxicity  as  well  as  on  primary  cortical  neurons.  
This  was  one  instance  in  this  project  where  the  data  did  not  agree  with  our  initial  
hypothesis.   We   expected   for   IL-­1a   to   require   interaction   with   the   vascular  
endothelium   and   basement   membrane   in   order   for   it   to   impart   its   protection.  
However,  the  results  in  Figure  2.1  showed  us  that  IL-­1a  could  be  acting  in  a  much  
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more  pleiotropic  way.  We  revised  our  hypothesize  to  say  that  IL-­1a  may  not  require  
any  downstream  signaling  and  could  act  centrally  upon  a  little-­studied  receptor  IL-­
1R3   (109)   found   on   neuronal   cell   membranes.   Alternatively,   our   previously  
published  data  suggests  that  neurons  could  be  producing  LG3  independently  of  
endothelial  cell  input  through  an  IL-­1a-­induced  upregulation  (99).  
Indeed,   some,   if   not   all,   neuroprotective   actions   of   IL-­1a   are   believed   to   be  
triggered   independently  of   the  classical   receptor   IL-­1R1   (160),  and  others  have  
reported  IL-­1R1-­independent  IL-­1a  actions  in  the  brain  (156).  One  study  from  2012  
established   that   IL-­1a   interacts   with   IL-­1R3   to   mediate   changes   in   potassium  
current   through  activation  of  Akt  kinase   (109).  Because  of   this,  we  hypothesize  
that  IL-­1a  could  be  triggering  the  PI3K/Akt  signaling  pathway  through  this  receptor  
(instead  of  IL-­1R1)  to  elicit  its  observed  neuroprotective  effects.  The  testing  of  this  
hypothesis   is   beyond   the   scope   of   this   project;;   however,   future   studies   will  
undoubtedly  include  elucidating  the  mechanism  behind  IL-­1a’s  activity.    
Clinical  Relevance  and  Future  Directions:  
While  the  above  data  are  promising,  it  will  take  some  time  for  the  dogma  that  “all  
inflammation  is  bad  inflammation”  to  be  reversed.  Even  with  the  preclinical  data  
showing  that  IL-­1a,  in  certain  quantities,  is  safe,  few  surgeons  will  willingly  inject  a  
pro-­inflammatory   cytokine   into   a   patient   actively   suffering   a   stroke.   The   data  
presented  here  is,  however,  highly  relevant  to  preclinical  work  in  that  it  is  helping  
to  discover  why  anakinra   trials  have   failed.   It  has  also  been   instrumental   in   the  
discovery   of   IL-­1a’s   downstream   actions   which   we   have   shown   to   be   both  
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beneficial  and  independent  of   IL-­1b’s  action.  There  are  several  questions  which  
remain  unanswered  by  this  work  which  will  need  to  be  answered  before  true  clinical  
translation  is  possible.  
One  such  question,  which  is  actively  being  investigated,  is  determining  the  role  of  
cell-­specific   IL-­1R1  contributions   to   IL-­1a’s  downstream  signalling.  Others  have  
shown   that   WT   and   IL-­1a   KO   animals   experience   better   outcomes   following  
experimental  stroke  by  blocking  IL-­1R1  with  IL-­1RA,  but  that  IL-­1b  and  IL-­1a/b  do  
not   experience   the   same   protection   (161).  We   hypothesize   that   this   is   due   to  
abolishing  the  negative  effects  of  IL-­1b  rather  than  those  of  IL-­1a.  Additionally,  for  
reasons  outlined  above,  we  are  reticent   to  put   too  much  store   into  experiments  
dependent   on   genetic   deletion   (particularly   pan-­deletions)   and   so   we   will   first  
perform  experiments  in  brain  endothelial  cell  specific  IL-­1R1  KO  animals  (BEC  IL-­
1R1  KO),  thus  minimizing  widespread  compensation.  There  is  still  a  risk  of  faulty  
design   here   due   to   the   previous   finding   that   peripheral   exosomes   can   traffic  
membrane   bound   proteins   (potentially   receptors)   to   other   organ   systems   thus  
compensating  for  the  IL-­1R1  deletion  (162,  163).    
Another   way   to   investigate   IL-­1a’s   specific   signalling   mechanism   would   be   to  
selectively  neutralize  IL-­1a  using  a  neutralizing  antibody.  While  this  method  should  
provide  a  less  invasive  way  of  determining  IL-­1a’s  benefit  in  the  context  of  stroke,  
the  route  of  administration  presents  a  problem.  IL-­1a  is  characteristically  not  found  
in  serum  of  healthy  individuals  and  so  systemic  pretreatment  (IV  or  IP)  is  already  
not   ideal.  Waiting  until  after  stroke   to  give   the  antibody   IV  or   IP  would  be  more  
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likely  to  reach  its  target  in  the  serum  but  would  be  unlikely  to  cross  even  the  leaking  
BBB  in  time  to  affect  IL-­1a  as  it   is  upregulated  so  rapidly  following  stroke  onset  
(83)  and   remains  elevated  chronically   (118).  An  alternative   is   to  administer   the  
antibody   via   intrathecal   injection   thereby   selectively   affecting   central   nervous  
system  sources  of  IL-­1a  (microglia).  However,  the  additional  hole  drilled  into  the  
skull  significantly  increases  the  invasiveness  of  the  stroke  procedure.  Additionally,  
this  would  only  affect  acute  sources  of   IL-­1a   thus  requiring  additional   injections  
where  similar  technical  challenges  would  be  faced.  Taken  together,  studying  the  
selective   effects   of   endogenous   IL-­1a   in   stroke   is   a   necessary   but   highly  
technically  difficult  and  will  likely  require  its  own  project  altogether.  
Another   future   challenge   for   this   project   going   forward   will   be   confirming  
inflammatory   cell   contributions   to   IL-­1a   production   in   more   chronic   phases   of  
stroke.  Based   on   the   results   from   the  Buckwalter   group   at   Stanford,   infiltrating  
immune  cells  are   largely   to  blame  for   the  sustained  IL-­1a  expression  within   the  
stroke-­injured  area  nearly  two  months  after  stroke  (118).  In  Figures  2.3  and  4.1,  
we  show   (what  we  believe)   are  microglia   either   co-­labeled  with,   or   affected  by  
treatment  with  IL-­1a.  Unfortunately,  our  immunohistochemical  method  of  labeling  
reactive   microglia   is   complicated   by   the   fact   that   both   Iba-­1   and   CD11b   are  
markers  that  label  both  resident  microglia  as  well  as  infiltrating  monocytes  (such  
as  neutrophils  which  have  been  implicated  in  propagating  and  worsening  injury)  
(118,  128,  164).  Therefore,  it  is  important  to  discover  which  cell  type  is  producing  
IL-­1a  at  each  phase  following  stroke.  If  infiltrating  cells  are  responsible,  it  is  unlikely  
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that  the  beneficial  effects  of  IL-­1a  will  be  capable  of  outweighing  the  detrimental  
effects  of  infiltrating  monocytes  such  as  neutrophils  thus  limiting  its  potential  as  a  
therapeutic.  Fortunately,  our  lab  is  also  investigating  drugs  which  act  by  preventing  
the   BBB   from   opening   which   could   be   used   to   address   the   infiltration   of   pro-­
inflammatory,  damaging  cell  types  in  the  brain,  thereby  removing  a  source  of  IL-­
1a-­independent  damage.  
Regarding  IL-­1a’s  mechanism,  data  suggesting  that  IL-­1a  acts  through  perlecan’s  
LG3  fragment  has  introduced  an  entirely  novel  project  into  the  lab  and  has  opened  
up  new  opportunities   for   future  NIH   funding.  Preliminary  data   in  our   lab   is  now  
showing   the  LG3  alone  can   impart  neuroprotection  when  given   through  both   IA  
and  IV  administration  and  also  can  help  improve  functional  recovery.  We  also  have  
early  data  showing  that  LG3  is  directly  protective  on  neurons.  Finally,  another  lab  
has  recently  published  that  cathepsin  b,  one  of  the  principle  proteases  involved  in  
perlecan/LG3   proteolysis   is   instrumental   in   exercise-­induced   cognitive  
improvement.  A  budding  project  investigating  LG3  as  a  theronostic  (a  new  concept  
that   suggests   a   situation   where   a   biomarker   which   can   also   be   used   as   a  
therapeutic  (165))  in  the  context  of  stroke  and  exercise  has  also  stemmed  from  the  
work  presented  here.  So,  while  IL-­1a  may  not  be  the  answer  to  stroke,  its  study  
has  certainly   led  our   lab   to  be  one  step  closer   to  uncovering  a  new  therapeutic  






Figure  5.1  Graphical  summary  of  hypothesized  IL-­1a  mechanism(s)  of  action.  (A)  
IL-­1a  binds  IL-­1R1  on  the  luminal  surface  of  vascular  endothelial  cells  which  drives  
the  recruitment  of   its  signaling  complex.  This   IL-­1a-­mediated  signaling  complex  
upregulates   OR   activated   NF-­kB   which   is   transported   to   the   nucleus   where   it  
drives   the   transcription   of   perlecan   and   cathepsin   B   thereby   producing   the  















In   conclusion,   the   work   presented   in   this   dissertation   shows   that   IL-­1a   is   an  
attractive   therapeutic   target   in   the   context   of   stroke.   However,   because   of   its  
narrow   therapeutic   window   and   its   potentially   damaging   effects   when   given   in  
excess,  its  downstream  factors  such  as  perlecan  LG3  may  be  a  better  target  for  
future  preclinical  translation.  
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Appendix  A:  
List  of  Abbreviations  
IL-­1  =  interleukin  1    
IL-­1a  =  interleukin  1  alpha  
IL-­1b  =  interleukin  1  beta  
CXCL-­1  =  chemokine  (C-­X-­C  motif)  ligand  1  
IL-­6  =  Interleukin  6  
IL-­1R  =  interleukin  1  receptor  
IL-­1RA  =  Interleukin  1  receptor  antagonist  
LG3  =  laminin  globular  domain  3    
BBB  =  blood-­brain  barrier  
CNS  =  central  nervous  system  
CCA  =  common  carotid  artery  
MCA  =  middle  cerebral  artery  
MCAo  =  middle  cerebral  artery  occlusion  
Pln  KO  =  perlecan  hypomorph  
ELISA  =  enzyme-­linked  immunosorbent  assay    
BEC  =  brain  endothelial  cell  
MTS  =  3-­(4,5-­dimethylthiazol-­2-­yl)-­5-­(3-­carboxymethoxyphenyl)-­2-­(4-­sulfophenyl)  
-­2H-­tetrazolium  
ANOVA  =  analysis  of  variance  




















Parameter Response Points Score
Alert 0
Arousal to Stimuli 1
Obtunded 2
Left Eye - Normal 0
Left Eye - Deficit 1
Right Eye - Normal 0
Right Eye - Deficit 1
Normal 0
Hemianopia/Deficit 1
Front Left - Normal 0
Front Left - Deficit 1
Front Right - Normal 0
Front Right - Deficit 1
Back Left - Normal 0
Back Left - Deficit 1
Back Right - Normal 0





Total Score (max. 11) 
Arousal to Stimuli (1) – physical touch to stimulate walking; unkempt fur; moves but stays in same location
Neurological Score for Stroke Severity
Date:
Day Tested (Baseline, PSD, etc.):
Level of Consciousness






** Note - All subjects have only five (5) seconds to complete each task (except the paralysis-paw hang)**
Paralysis (2) – unable to hold onto wooden dowel for 60 seconds; releases both paws from dowel completely
Notes
** (note - any movements other than those above do not classify as a normal response) **
Normal (0) – mouse on flat surface; able to detect pressure on paw; squeaks, rears, or withdraws leg/paw
Partial (1) – able to hold onto wooden dowel for 60 seconds; completely release one paw; paw is not resting on any portion of dowel
Normal (0) – able to hold onto wooden dowel for 60 seconds without losing grip; both paws are on dowel
Paralysis
Deficit (1) – mouse on flat surface; unable to detect pressure on paw; no squeaking, rearing, or withdrawing leg/paw
Obtunded (2) – unable to arouse; mouse in hunched position with unkempt fur; no movement
Gaze
Normal (0) – acknowledges finger when placed in left and right visual fields; rears head towards finger
Sensory
Hemianopia/Deficit (1) – unable to detect lateral movement towards table edge; no reaching
Normal (0) – able to detect lateral movement towards table edge; reaches out to grab table
Visual Field
Deficit (1) – no response to the presence of the finger; no rearing towards finger
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